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1 Glossary 
ASC: Adult stem cell 
Bmp2: Bone morphogenetic protein 2 
CB: Cardiac body 
CVPC: Cardiovascular progenitor cell 
CMC: Cardiomyocyte 
cTnT: Cardiac troponin T 
EB: Embryoid body 
ERK1/2: Extracellular signal related kinase 1/2 
ESC: Embryonic stem cell 
FBS: Fetal bovine serum 
FGF4: Fibroblast growth factor 4 
Gap1: GTPase activating enzyme 1 
Grb2: Growth factor receptor binding protein 2 
GSK3: Glycogen synthase kinase 3 
Id 1: Inhibitor of DNA binding and differentiation 1 
iPS: Induced pluripotent cells 
JAK: Janus-Kinase,  
Klf4: Krüppel-like factor 4  
LIF: Leukemia inhibitory factor 
LIFR: Leukemia inhibitory factor receptor 
MAPK: Mitogen activated protein kinase 
MEK 1/2: MAP-ERK kinase 1/2 
mESC: Mouse embryonic stem cells 
Nanog: Tir na og [celtic: Land of eternal youth] 
Nkx2.5: NK2 transcription factor related, locus 5 
Oct 3/4: Octamere binding factor 3/4 
SDS-PAGE: Sodium dodecylsulfate polyacrylamide gel electrophoresis 
PI3K: Phosphatidylinositol-3-OH kinase 
pou5f: Pou-domain, class5, transcription factor1 (coding for Oct3/4) 
qPCR: Quantitative polymerase chain reaction or real time PCR 
Ras: Rat sarcoma  
RT-PCR: Reverse transcriptase polymerase chain reaction 
SF9: Insect cell line established from Spodoptera frugiperda 
SCNT: Somatic cell nuclear transfer 
Sos: Son of sevenless (D. melanogaster) 
Sox2: SRY (sex determining region Y) box 2 
SPARC: Secreted protein acidic and rich in cysteine 
SRY:  Sex determination region Y 
STAT3: Signal Transducer and activator of transcription 3 
Tbx3: T-box transcription factor 3 
TGFβ: Transforming growth factor β 
Wnt: Signaling pathway, the name Wnt is a combination of Wg (wingless) and Int gene 
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2 Introduction 
Stem cells are one of the most important fields of research in modern molecular 
biology which will provide answers to fundamental scientific questions. Stem cells have 
the unique property of self-renewal and potency which means that they are able to 
differentiate into many different cell types. The regulatory mechanisms which regulate 
stem cell self-renewal and differentiation are still not fully understood. During 
embryogenesis embryonic stem cells (ESCs) differentiate into all cell types of the body 
in a strictly regulated manner. Thus, studying ESCs provides information on how they 
differentiate into the various cells of the body and how this differentiation is regulated. 
Furthermore, in organs of adult organisms like bone marrow, brain, skeletal muscle, 
skin, intestine liver, testis etc. stem cells are present called adult stem cells (ASCs). 
These ASCs have a restricted differentiation potential which means they can only 
differentiate into certain cells of an organ. ASCs have two essential functions which are 
tissue renewal and tissue damage repair. Continuous tissue renewal is necessary in 
organs like the skin or the intestine, where ASCs replenish aged cells. Tissue damage 
repair is needed for regeneration of injured organs. The regenerative function of ASCs 
in adults makes them especially interesting for medical researchers because of their 
potential use in stem cell therapy. ASCs, for example could be used for regeneration of 
injured tissues and organs or replacement of tissues. The first successful treatment 
using ASCs was the first successful hematopoietic stem cell transplantation, which was 
performed by Robert A. Good in 1968. Since then it is routinely used for the treatment 
of leukemia and related bone and blood cancers. Development of new adult stem cell 
therapies is still in progress.  
A prime example for a potential application of a new stem cell therapy is 
cardiovascular disease (CVD). CVDs include several diseases of the heart and blood 
vessels like coronary heart disease, cerebrovascular disease, peripheral artery disease, 
rheumatic heart disease, congenital heart disease and heart failure. CVDs are the 
number one cause of death worldwide. In 2004 17.1 million people died from CVDs of 
which an estimated 7.2 million were due to coronary heart disease (WHO, 2009). 
During CVDs lack of oxygen in the heart tissue can lead to apoptosis of cardiomyocytes. 
This loss of cells is irreversible and often leads to a lethal progressive heart failure 
which can only be treated by heart transplantation. However, there are not enough 
donor organs for each patient and heart transplantation is a treatment but not a cure. 
The 1-year survival rate is over 80% and the average length of survival is 9.1 years (Jurt 
et al. 2002). For CVD-patients lack of donor organs could be circumvented and a 
complete healing could be achieved by transplantation of stem cells. Several clinical 
trials using bone-marrow derived hematopoetic stem cells and skeletal myoblasts 
where done in humans but showed modest success. Studies in animal models showed 
that stem cells are present in adult hearts (Joggerst and Hatzopoulos 2009). Studies 
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with rats showed that adult cardiac stem cells exist, which support myocardial 
regeneration (Beltrami et al. 2003). According to these studies, the most promising 
approach to heal and regenerate the injured heart tissue is to inject ASCs of the heart 
into the typical necrotic areas (Figure). 
 
 
Figure 1: Illustration of a stem cell therapy for an infarcted heart. The balloon catheter enters the infarct-related 
artery and is placed above the border zone of the infarction. The catheter is then inflated and the cell suspension 
(including the patient's own cytokines) is infused at high pressure under stop-flow conditions. In this way, cells are 
transplanted into the infarcted zone through the infarct-related vessel system. Cells and cytokines infiltrate the 
infarcted zone. The arrows show the possible route of cell migration and cytokine infiltration. LAD, left anterior 
descending coronary artery; LCX, left circumflex artery; RCA, right coronary artery. (Adapted from Brehm 2006) 
To obtain a sufficient quantity of adult cardiac stem cells for a stem cell therapy it will 
be necessary to cultivate and expand them in an in vitro culture. For directed and 
specific differentiation of ADCs to adult heart cells it is mandatory to understand which 
factors are responsible and which signalling pathways are regulated during 
differentiation. The first step is to establish an animal model for isolation and specific 
differentiation of cardiac ADCs. The ability to isolate, cultivate and handle cardiac stem 
cells will lead to the development of therapies for cardiovascular disease.  
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2.1 Stem cells  
A stem cell is defined by two unique properties distinguishing it from any other cell: 
• Self renewal, which means the ability to go through unlimited cell division 
cycles without differentiating. 
• Potency, which means the capacity to differentiate into at least one cell type.  
All stem cells have the capability of self renewal. The potency specifies the 
differentiation potential and differs in different stem cells. It can be subdivided into 5 
classes: 
1. Totipotency, is the ability to differentiate into any cell of the body. Totipotent 
cells can give rise to embryonic and extra-embryonic cells like placenta cells. A 
fertilized ovum is totipotent. 
2. Pluripotency, means the ability to differentiate into any cell except 
extraembryonic cells. Examples are embryonic stem cells. 
3. Multipotency, describes the ability of stem cells to differentiate into several 
different cell types. Hematopoetic stem cells for example give rise to all blood 
cells. 
4. Oligopotency, is a property of stem cells which differentiate into few cell types. 
Lymphoid stem cells for example differentiate to B-, T- and natural killer cells. 
5. Unipotency, is the ability to differentiate into only one cell type. An example is 
spermatogonial cells. 
2.1.1 Sources of stem cells 
• Embryonic stem cells are stem cells isolated from the inner cell mass of 
blastocysts and are pluripotent. 
• Somatic Cell Nuclear Transfer (SCNT). The nucleus of an oocyte is removed and 
the nucleus of a somatic cell is transferred into the oocyte. The resulting cell is 
pluripotent and gives rise to the embryo. All daughter cells are clones of the 
nucleus-donor. This process is also referred to as cloning. SCNT can be used for 
therapeutic cloning or reproductive cloning. 
• Induced pluripotent stem cells (iPS) are genetically reprogrammed adult cells 
which resemble embryonic stem cells. Genetic modifications like expression of 
certain transcription factors are achieved by retroviral expression vectors. 
Possible differences to ESC are not fully tested yet. iPS cells are pluripotent. 
• Embryonic germ cells can be isolated from the gonadal ridge of fetal tissue and 
are multipotent. 
• Adult stem cells are stem cells which reside in tissues of the adult organism. 
ASCs have a limited potency and are multi-, oligo- or unipotent. 
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2.1.2 Embryonic stem cells  
The fertilized oocyte is called zygote and represents the first ESC during 
embryogenesis. The zygote first undergoes cleavage in which it divides without 
growth. Afterwards, at the blastula stage the spherical embryo begins to form a fluid 
filled cavity called blastocoel. The resulting blastocyst contains cells inside the 
blastocoel called inner cell mass. These cells of the inner cell mass are the pluripotent 
ESCs which can be isolated for in vitro culture. Murine embryonic stem cells (mESCs) 
where first isolated from mouse blastocysts from the epiblast tissue of the inner cell 
mass by Martin Evans (Evans and Hunter 2002), Matthew Kaufman and separately and 
simultaneously by Gail R. Martin in 1981. In 1998 the first human embryonic stem cells 
were isolated by J. Thomson et al. (Thomson et al. 1998) (Figure 2). 
 
 
 
Figure 1: Embryonic stem cells (ESCs) isolated from the inner cell mass (ICM). ESCs can be isolated from the inner 
cell mass of an embryo at the blastocyst stage. ESCs from the inner cell mass are pluripotent and are able to 
differentiate to any cell type except extraembryonic tissue like the placenta. (Figure from Biotechnology Learning 
Hub) 
 
Since pluripotent mESCs were first established they have been cultivated and 
maintained undifferentiated and pluripotent in vitro, using different combinations of 
feeder cells, cytokines, fetal calf sera and conditioned media to prevent differentiation. 
The most common procedure to cultivate isolated mESCs is to let them grow on a 
feeder cell layer consisting of STO SNL76/7 mouse fibroblasts. The feeder cells provide 
a matrix to which the ESCs can attach and they secrete cytokines like leukemia 
inhibitory factor (LIF). The secreted LIF together with bone morphogenetic protein 2 
(BMP2), which is a component of the fetal bovine serum added to the medium, is 
sufficient to keep mESCs undifferentiated.   
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2.2 Embryoid bodies 
Embryoid bodies (EBs) are aggregates of ESCs and represent an in vitro differentiation 
model of embryogenesis. A commonly used method to form EBs is to aggregate mESCs 
in hanging droplet culture. In hanging drops the ESCs form a compact sphere called 
embryoid body. After this aggregation ESCs start to differentiate into cell types of all 
three germ layers (endoderm, ectoderm and mesoderm). Every cell type present in the 
early embryo develops with the exception of trophectodermal tissue which forms the 
placenta in vivo. Cysts form in the EBs and mesodermal cells differentiate to beating 
cardiomyocytes which can be observed within a few days of differentiation. 
 
2.2.1 Regulation of murine embryonic stem cell pluripotency 
In contrast to the classic view that mESCs have to be treated with factors to maintain 
pluripotency, Austin Smith et al (Ying et al. 2008) showed that mESCs have an innate 
capability to self-renew and replicate which doesn’t depend on extrinsic factors. The 
auto-regulative expression of the three key transcription factors Oct3/4, Sox2 and 
Nanog (Masui et al. 2007) in mESCs is essential to maintain pluripotency. Therefore 
Oct3/4, Sox2 and Nanog are called stemness factors which are present in all stem cells.  
• OCT3/4 (Octamere binding factor 3/4) is a homeodomain transcription factor 
and belongs to the POU (Pit/Oct/Unc) family. Oct3/4 is an essential stemness 
factor and all undifferentiated stem cells express Oct3/4. In mESCs Oct3/4 
expression prevents differentiation. A knockdown of Oct3/4 induces 
differentiation (Zaehres et al. 2005). If Oct3/4 is repressed at the morula stage 
of the mouse embryo, mESCs differentiate to trophoectoderm (Figure3). 
Oct3/4 expression is also observed in several adult stem cells (Ling et al. 2006). 
• Nanog is a NK-2 class homeobox transcription factor which is also essential for 
self-renewal of mESCs. mESCs start to differentiate to primitive endoderm 
without Nanog expression (Mitsui et al. 2003). Overexpression of Nanog in 
mESCs is sufficient to keep them undifferentiated in absence of LIF.  
• Sox2 (sex determining region Y)-box 2 is a transcription factor and belongs to 
the SRY related HMG-box (SOX) transcription factor family. Sox2 expression is 
essential for mESC self renewal. 
Oct3/4, Sox2 and Nanog build a transcriptional network and regulate the expression of 
each other by feedback loops. Oct3/4 and Sox2 bind to each other and activate Oct3-
Sox enhancers which regulate stem cell specific gene expression and the expression of 
the 3 stemness factors themselves (Masui et al. 2007). How the regulation exactly 
works is not fully discovered yet. Downregulation of the three stemness factors 
correlates with differentiation. 
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Figure 2: Regulation of stemness factors Oct3/4 and Nanog during embryogenesis. At the morula stage cells 
without Oct3/4 expression differentiate to trophoectoderm. In the early blasotocyst cells of the inner cell mass can 
only differentiate to pluripotent epiblast cells if Nanog is expressed, otherwise they become primitive endoderm. 
The epiblast tissue is the source of pluripotent ESCs which express Oct3/4, Nanog and Sox2. (Adapted from Niwa, 
2007) 
 
mESCs are susceptible to differentiation signals, which may drive them towards 
commitment when expression and autocrine secretion of fibroblast growth factor 4 
(FGF4) is induced by Oct3/4 and Sox2. Upon activation of the FGF4-receptor by FGF4 
the tyrosine kinase of the FGF4 receptor activates the MAPK (mitogen activated 
protein kinase) Erk1/2 (Extracellular Signal-Regulated Kinases 1 and 2) pathway which 
ends the pluripotent state and leads towards commitment (Ying et al. 2008). 
The susceptibility to commitment can be prevented by specifically inhibiting the Erk1/2 
pathway activated by FGF4 (Figure 4). The 2 molecules SU5402 and PD184352 
specifically inhibit the FGF4 receptor tyrosine kinase thereby blocking the activation of 
the ERK1/2 kinase. Inhibiting the ERK1/2 pathway is sufficient to maintain pluripotency 
in mESCs but the apoptosis rate is high and cell growth and viability is impaired. To 
overcome this problem a new specific inhibitor of glycogen synthase kinase 3 (GSK3) 
the chemical CHIR99021 was utilized, referring to reports (Sato et al. 2004) that 
inhibition of GSK3 enhances mESCs viability. mESCs treated with CHIR99021 in 
combination with SU5402 and PD184352 remained pluripotent, viable and showed a 
normal proliferation rate. In summary, it was shown that commitment can be inhibited 
by blocking the ERK1/2 pathway and by GSK3 inhibition when mESCs are treated with 
the 3 specific inhibitors CHIR99021, SU5402 and PD184352, called ‘3i’. 
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Figure 4: Inhibtion of commitment in mESCs by blocking the Erk1/2 MAPK-pathway and GSK3. FGF4 induced 
commitment can be inhibited upstream of the ERK1/2 pathway by inhibitors SU5402 and PD184352. Additional 
inhibition of GSK3 by CHIR99021 is needed to maintain cellular growth and viability (Adapted from Ying et al, 2008). 
 
In conventional mESCs culture commitment was always blocked with LIF and BMP2, 
but the exact pathways responsible were unknown. Although LIF and BMP2 act 
downstream of the MAPK pathway, administering LIF and BMP together is sufficient to 
maintain mESCs undifferentiated (Figure 2). mESCs can be successfully propagated by 
cultivation on a feeder cell layer of SNL76/7 STO mouse fibroblasts which secrete LIF. 
Alternatively LIF can be administered to the cultivation medium. Furthermore the fetal 
bovine serum or fetal calve serum in the medium with which cells are fed contains 
BMPs.  
 
 
Figure 5: BMP2 and LIF inhibit commitment downstream of ERK1/2 pathway. BMP2 present in the serum of cell 
culture medium and LIF secreted by feeders are sufficient to inhibit FGF4 induced commitment in mESCs. Viability is 
increased by LIF(Adapted from Ying et al, 2008). 
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2.3 Leukemia inhibitory factor and bone morphogenetic protein 2 in 
self-renewal 
   
Figure 6: Structure of LIF (RCSB Proteine Data Bank) 
 
Leukemia inhibitory factor (LIF) (Figure 6) derives its name from the ability to induce 
terminal differentiation of myeloid leukemic cells. It is a glycoprotein belonging to the 
Interleukin-6 class cytokines. LIF is pleiotrop, it has different effects on different cell 
types and tissues. On the one hand it is used to maintain mESCs undifferentiated in cell 
culture, on the other hand it is known for the growth promotion and cell 
differentiation of different types of target cells, and its influence on bone metabolism, 
cachexia, neural development, inflammation and embryogenesis. In mESCs culture LIF 
is added to the medium or secreted by feeder cells because mESCs spontaneously 
differentiate without LIF. In the developing embryo LIF is expressed in the 
trophoectoderm, and the LIF-receptor (LIFR) is expressed throughout the inner cell 
mass (ICM). As mESCs are derived from the ICM at the blastocyst stage, removing 
them from the ICM also removes their source of LIF. Without LIF mESCs lose their 
totipotency and start to differentiate. Therefore LIF has to be added to the medium in 
mESCs culture. mESCs are usually cultivated on a feeder cell layer, consisting of 
transformed mouse fibroblasts which express and provide them with LIF. Interestingly 
LIF is not required for culture of human embryonic stem cells.  
The mouse LIF-gene codes for three different isoforms of LIF: truncated LIF (T-LIF), 
matrix associated LIF (M-LIF) and diffusible LIF (D-LIF), which are generated by 
alternative splicing (Rathjen et al. 1990). M and D-LIF have the same size and sequence 
except in their N-terminal aminoacid-sequence, a putative leader sequence, and are 
both secreted by cells. Truncated LIF remains inside the cell. Altough M-LIF and D- LIF 
are both secreted they may have different effects (Stary et al. 2006). 
In mESCs LIF binds to heterodimers of gp130 receptor and LIF receptor (LIFR) which 
leads to activation of 3 different pathways (Figure 7): The Jak-Stat3 pathway, 
phosphatidylinositol-3-OH kinase (PI3K)-Akt and Erk1/2 pathway (Niwa et al. 2009). 
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1. Notably the Jak-Stat3 pathway is the only one of the 3 LIF-activated pathways 
in mESCs which is activated by LIF alone. After heterodimerization of gp130 and 
LIFR associated Janus kinase (Jak) becomes activated by phosphorylation and 
phosphorylates signal transducer and activator of transcription 3 (Stat3). 
Phosphorylated Stat3 homodimers translocate into the nucleus and activate 
the nuclear transcription factor Krüppel-like factor 4 (Klf4) which induces Sox2 
and Nanog transcription.  
2. The PI3K pathway is regulated by LIF, insulin, insulin-like growth factors and a 
rat sarcoma (Ras) like protein kinase called Eras (Takahashi et al. 2003), which is 
constitutively active in mESCs. Activated PI3K leads to activation of T-box 
transcription factor 3 (Tbx3) and Nanog (Storm et al. 2007). 
3. The Erk1/2 pathway is a pathway which promotes differentiation in mESCs and 
is also induced by the autocrine FGF4 signaling (see chapter 4.1). Erk1/2 
pathway is activated when Jak phosphorylates “Growth factor receptor-bound 
protein 2” (Grb2) which starts the MAPK signaling cascade including the 
proteins “Son of Sevenless” (Sos), Ras, Raf and Erk1/2. Erk1/2 promotes 
differentiation by stimulating the nuclear export of Tbx3. 
The Jak-Stat3 pathway which is solely regulated by LIF induces self renewal in 
mESCs. The Erk1/2 pathway induces differentiation in mESCs. The PI3K and the 
Erk1/2 pathways are influenced by other signals than LIF as well. Interestingly all 3 
pathways act on Klf4 and Tbx3 which influence the expression of the 3 stemness 
factors Oct3/4, Sox2 and Nanog. Thus, these two transcription factors link LIF to 
the transcriptional network of self renewal. Recent experiments confirmed this 
finding when mESCs where transfected with Tbx3 and Klf4. Transfected mESCs 
could be cultivated and remained pluripotent in absence of LIF (Niwa et al. 2009). 
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Figure 7: LIF is connected to the pluripotency network: LIF induces Jak/STAT3 and PI3K (Akt) pathways which 
activate transcription factors Klf4 and Tbx3. Activated Klf4 and Tbx3 upregulate Sox2 and Nanog expression. The 
alternatively activated MAPK pathway inhibits pluripotency by inhibiting nuclear localization of Tbx3 (From Niwa, 
2009). 
 
Nevertheless, previous experiments with EBs showed a promoting effect of LIF on 
cardiomyogenesisin in studies by Bader et al (Bader et al. 2001). Moreover, LIF 
activates Stat3 by phosphorylation and in the cardiac marker gene Nkx2.5 Stat3-
specific binding sequences are present in the promoter region. 
2.4 Bone morphogenetic proteins 
The cytokine bone morphogenetic factor 2 (BMP2) belongs to the transforming growth 
factor β (TGF-β) super-family. The BMP group comprises at least 7 BMPs. Its name is 
derived from the ability to induce ectopic bone formation in rodents. BMP2 binds to 
heterodimers of BMP receptor type I (BMPRI) and BMP receptor type II (BMPRII). The 
serine threonine kinase domain of activated BMPRI and BMPRII phosphorylates 
Smad1/5/8 which binds to Smad4 and translocates to the nucleus. In the nucleus the 
Smad complex can inhibit or promote gene expression when binding to transcriptional 
activators or transcriptional repressors. In mESCs culture BMPs are present in the fetal 
calf serum. When a serum free medium and no feeder cells are used, a combination of 
LIF and BMP4 or BMP2 is sufficient to maintain pluripotency and self renewal (Ying et 
al. 2003). In undifferentiated mESCs BMP activates Smad1/5/8 which promotes 
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inhibitor of differentiation (Id) expression. mESCs transfected with Id remain 
pluripotent when cultured in serum free medium with LIF. 
BMP2 expression is essential during embryogenesis. Without BMP2 early embryos 
have an abnormal cardiac development and fail in amnion and chorion formation 
(Zhang and Bradley 1996). BMP2 is essential for early heart development and induces 
expression of cardiac marker genes like Nkx2.5 and GATA4 (Schlange et al. 2000). 
Besides maintaining pluripotency in mESCs, BMPs like LIF can also induce 
differentiation. In neural progenitors, differentiation to astrocytes is induced by LIF 
and BMP2. The transcriptional coactivator p300 binds to both LIF induced STAT3 and 
BMP induced SMAD1 (Nakashima et al. 1999). Thus, LIF and BMP can cooperatively 
induce differentiation in neural progenitor cells or maintain pluripotency in mESCs. 
 
2.5 Secreted protein acidic and rich in cysteine (SPARC, Osteonectin, 
BM-40) 
SPARC, also called osteonectin, 43K protein or BM-40, is an extracellular Ca²
+
 binding 
matricellular glycoprotein and has versatile effects on cells undergoing migration, 
morphogenesis and differentiation. Its main functions are counter-adhesion and anti-
proliferation which are induced by activating different pathways. SPARC consists of 3 
domains. The N-terminal acidic Ca
2+
-binding domain binds Ca
2+
 with low affinity 
(Maurer et al. 1992) and interacts
 
with hydroxyapatite (Romberg et al. 1985). It has 
therefore been implicated in the mineralization of cartilage and bone (Figure 8). The 
second domain contains follistatin-like sequences and stimulates cell proliferation and 
angiogenesis (Funk and Sage 1993). The third domain is extracellular and consists of a 
largely α-helical high affinity Ca
2+
-binding domain with a binding site for collagen IV. 
SPARC is expressed in different tissues and has an effect on remodeling and repair. 
During embryogenesis SPARC is expressed in heart primordia, somites, and 
extraembryonic membranes. SPARC interacts with growth factors like VEGF, FGF2 and 
PDGF and binds to extracellular matrix and cell surface proteins. It was shown that 
SPARC is expressed during muscle development and during regeneration of muscle 
tissue. Expression of SPARC was found in myoblasts and also in myotubes and muscle 
fibers. The degree of SPARC expression in regenerating myotubes correlates with the 
severity of myotube injuries (Jorgensen et al. 2009). 
SPARC activates the TGF-ß pathway and interacts with integrin linked kinase 1 (ILK1) 
(Brekken and Sage 2000). ILK1 phosphorylates protein kinase B (PKB/Akt) and GSK3 
(Persad et al., 2001b). Phosphorylation of GSK3 leads to upregulation of the Wnt-
pathway and nuclear ß-catenin. Wnt signaling upregulates the expression of the 
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cardiac transcription factor Nkx2.5. In myogenic differentiation ILK1 also regulates the 
Erk1/2 pathway by preventing Erk inactivation during myogenic differentiation. 
 
Figure 8:  Structure of SPARC: SPARC consist of 3 domains, an acidic Ca
2+
-binding domain, a follistatin like domain 
and a Ca
2+
-binding extracellular domain (Adapted from Qi Yan and E. Helene Sage, 1999). 
 
Martina Stary showed that SPARC is secreted by parietal endoderm and promotes 
cardiomyogenesis in EBs. Inhibition of SPARC inhibits cardiomyogenesis in EBs. In 
conjunction with BMP2 SPARC activates transcription of the cardiac marker gene 
Nkx2.5 (Stary et al. 2005). Thus, SPARC and BMP2 may enhance cardiomyogenesis in 
cardiovascular progenitor cells as well.  
2.6 Cardiovascular progenitor cells (CVPCs) 
Georg Weitzers laboratory has established 11 clones of a putative cardiovascular 
progenitor cell line (CVPC) isolated from heart tissue of neonatal mice. Heart cells from 
1 to 2 day old 129SvxC57BL6J hybrid mice, with a neomycin resistance gene insertion 
in one allele of the hdac1 locus, were isolated and co-cultured with an equal number 
of AB2.2 mouse embryonic stem cells on mitotically inactivated SNL76/7 mouse 
fibroblasts and LIF expressing parietal endoderm cells. After splitting 1:3 every third 
day for 10 passages, the cells were selected for neomycin resistance by treatment with 
G418, removing all AB2.2 mESCs (Pasteiner 2003; 2006). To exclude contamination by 
mESCs 100 cells obtained from one colony were seeded onto a 6cm plate on LIF 
expressing SNL76/7 feeder cells and treated with G418 for another 10 days. 12 
colonies were picked and 11 clonal cell lines could be derived, expanded and frozen 
(Wiedner 2008). The morphology of CVPCs is different to mESCs and karyotyping of 
those cells showed that fusion products of mESCs and heart cells can be excluded 
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(Wiedner 2008, Höbaus 2009). CVPCs can be maintained undifferentiated by 
cultivation on SNL76/7 feeder layers (Wiedner 2008). The CVPC cell line is still under 
investigation and self- renewal capacity and differentiation- potency is being 
determined. 
2.7 Conclusions and experimental setup 
To characterize CVPCs, first of all adult stem cell or progenitor cell characteristics had 
to be demonstrated. Based on research papers on CVPCs and mESCs an experimental 
strategy was developed for my diploma thesis. Wiedner (Wiedner 2008) showed that 
the CVPCs can be maintained undifferentiated just like mESCs by cultivation on LIF 
expressing feeder cells and feeding fetal calf serum containing BMPs. Therefore CVPCs 
will start differentiating in absence of feeder cells and without LIF. If CVPCs are 
multipotent but not pluripotent they will have a specific and restricted cardiovascular 
differentiation potential. Experiments in hanging drop culture and monolayer 
differentiation experiments should prove this. If CVPCs are stem cells, stem cell marker 
gene expression like Oct3/4 and Nanog and telomerase activity should be present. 
Expression of cardiovascular marker genes should be measured in undifferentiated and 
differentiated CVPCs. On protein level cardiovascular marker proteins like cardiac 
troponin T should be detectable by immunofluorescence in differentiated CVPCs. 
After successful maintenance of CVPCs and after verifying characteristics of a 
cardiovascular progenitor cell, differentiation mechanisms have to be investigated. In 
mESCs LIF and BMP2 inhibit differentiation and therefore have to be removed for 
differentiation. However, in somatic cells both factors induce differentiation. 
Therefore, a dual role of LIF and BMP2 in CPVCs is possible. LIF and BMP may activate 
different pathways to maintain self-renewal or pathways to induce differentiation (see 
chapter 4.2 and 4.3) depending on co-factors, dosage, cell density and time interval of 
treatment.  
SPARC promotes cardiomyogenesis in vitro in EBs and upregulates cardiac marker gene 
Nkx2.5 expression. Furthermore, SPARC is expressed in fetal myotubes and in 
regenerating myotubes. Thus, it is probable that SPARC promotes cardiomyocyte 
differentiation and promotes cardiomyocyte specific differentiation in CVPCs as well. 
SPARC is connected to the Wnt-pathway via ILK1 and Akt/PKB dependent 
phosphorylation and Wnt upregulates Nkx2.5 (Liu et al. 2009). Proof of this new 
pathway would explain upregulation of Nkx2.5 by SPARC. 
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3 Materials and Methods 
3.1 Chemicals for molecular biology 
Acetic acid Merck, D 
Acrylamide BioRad, USA 
Agarose, Biozyme LE Biozyme, D 
Aprotinin                                                                Sigma, USA 
BCIP (5’Brom-4’Chlor-3’Indoylphosphat) Diagnostic Chemicals                        
Limited, D 
ß-Mercaptoethanol Loba Feinchemie, A 
Bromphenolblue Sigma, USA 
BSA Roth, D 
Coomassie Brilliant Blue R250 Merck, D 
DAPI Sigma, USA 
Dabco Sigma, USA 
dNTPs MBI Fermentas, Lithuania 
Dimethylsulfoxid (DMSO) Acros, B 
Dimethylformamid Fluka, CH 
Dithiothreitol (DTT) Acros, B 
EDTA                                                                    Acros, B 
Ethanol Merck, D  
Ethidiumbromid Fluka, CH 
Formaldehyde Merck, D 
Glycerin Merck, D 
Hydrochloric acid (HCl) Acros, B 
Imidazole                                                                  Sigma, USA 
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Leupeptin                                                                     Sigma, USA 
Methanol Merck, D 
MgCl2 MBI Fermentas, Lithuania 
Mowiol 2-88 Hoechst, D 
NEB Buffer  New England Biolabs, USA 
Nitrotetrazolium Blue Chloride (NBT) Fluka, CH 
Ni-NTA agarose beads                                                  Quiagen, D 
PCR buffer without MgCl2 MBI, Fermentas, Lithuania 
Pepstatin A                                                                   Sigma, USA 
Ponceau-S Sigma, USA 
Reverse transcriptase buffer  Invitrogen, USA 
SDS BioRad, USA 
Sodiumbicarbonate                                                      Sigma, USA 
Sodiumchloride Salinen Austria, A 
Sodiumhydrogencarbonate LifeTechnologies, USA 
Sodiumhydrogenphosphate                                            Roth, D 
Sodiumhydroxide                                                    Merck, D 
Sodiumthiosulfate                                                        Merck, D 
Trichloracetic acid                                                      Merck D 
Tris Base LifeTechnologies, USA 
Tween-20                                                                   Sigma, USA 
 
3.2 Chemicals for cell culture 
ß-Mercaptoethanol Loba, A 
Ampothericin B Invitrogen, USA 
D-Glucose Acros, B 
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DMEM powder LifeTechnologies, USA 
DMSO (Dimethylsulfoxide) Sigma, USA 
Fetal Bovine Serum (FBS) HyClone, USA 
Fetal Bovine Serum (FBS) Gibco, USA 
Fetal Bovine Serum (FBS) Sigma, USA 
Gelatine Difco, USA 
Glycine                                                                        Applichem, D 
L-(+)-Glutamine Acros, B 
Mitomycin C   Acros, B 
 
Penicillin G Kaliumsalz Merck, D 
Penicillin / Streptomycin (P/S)                                  GibcoBRL 
Potassium chloride                                                     Sigma, USA 
Recombinant M-LIF                                                      Chemicon International 
Sf-900 SFM medium                                                      GibcoBRL 
Sodiumhydrongencarbonate LifeTechnologies, USA 
Streptomycin Sigma, USA 
 
3.3 Enzymes 
DNAse I, RNase free Fermentas 
RevertAid
TM
 M-MuLV RT Fermentas 
RiboLock RNase Inhibitor Fermentas 
RNaseOUT LifeTechnologies, USA 
Taq DNA Polymerase MBI Fermentas, Lithuania 
Trypsin LifeTechnologies, USA 
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3.4 Cell lines  
SNL76/7-Fibroblasts: 
This mouse fibroblast strain was established by Allan Bradley. It is based on STO 
fibroblasts, which were stably transfected with a neomycin resistance expression 
vector and a LIF expression vector (McMahon and Bradley, 1990). 
Ab2.2. Embryonic stem cells 
The embryonic stem cell line Ab2.2 was isolated by Allan Bradley from the inner cell 
mass of blastocysts of 129Sv mice in 1991. 
Cardiovascular Progenitor Cells: 
CVPC cell lines were isolated by Wolfgang Weber from heart tissue of HDAC1 +/- mice. 
This mouse line encodes a neomycin-resistance gene and can therefore survive 
selection with neomycin or neomycin analogs (e.g. G418). In order to increase survival 
rate of successful isolated cells, heart tissue derived cells were co-cultured with murine 
wild type embryonic stem cells Ab2.2. This co-culture was used to supply possible 
cardiovascular progenitor cells with external factors that are usually supplied by the 
stem cell niche. Since niche conditions are unknown, the presence of embryonic stem 
cells and the proteins, cytokines, etc. secreted by these, was thought to substitute for 
the stem cell niche. After 10 passages of co-culture (3T3 protocol) on feeder cells a 
selection against hypertrophic cells and towards fast replicating cells had already taken 
place. Addition of the neomycin analog G418 resulted in death of Ab2.2 embryonic 
stem cells. CVPC cells were cloned by seeding one cell per plate and expanding this 
culture under treatment of G418. 12 cell lines were derived named A3, A5, B3, B5, C3, 
D3, D5, E3, F3, G3, and H3. 
SF9-cells: 
SF-9 is an immortalized cell line derived from pupal ovarian cells of Spodoptera 
frugiperad. The SF-9 cell line is highly susceptible to infections with baculoviruses and 
can be used with all baculovirus expression vectors. SF9 cells are commonly used to 
produce recombinant proteins.  
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3.5 Culture of mammalian cells 
3.5.1 Washing of glass pipettes:  
After usage the cotton plug is removed and pipettes are put into vessels containing a 
mixture of water and hypochlorite. Glass pipettes are removed from the vessels and 
rinsed with fresh tab water for at least four hours. Afterwards pipettes are moved to a 
vessel containing Milli-Q water and are left there overnight. Pipettes are dried at 80°C 
for 4 hours and then placed in pipette boxes and baked at 180°C for 8 to 10 hours. If 
pipettes are contaminated with soap they can no longer be used for tissue culture of 
embryonic stem cells. 
3.5.2 Washing of bottles and other cell culture glass ware 
A small amount of hypochlorite is added to bottles and filled up to the top with tap 
water. After 15-30 minutes bottles are rinsed at least five times with tab water and 
then filled up with Milli-Q and left overnight. Then the bottles can be emptied and left 
upside-down till dry. Bottles are closed halfway and autoclaved at 120°C at 1.4 bar for 
20-30 minutes.  
Magnets and other tissue culture appliances are also washed with hypochlorite and 
Milli-Q prior to use and should solely be used for tissue culture and never come in 
contact with soap. 
3.5.3 Media and solutions for mammalian cell culture 
10x PBS (Phosphate buffered saline) 
 NaCl 80 g 
 KCl 2 g 
 Na2HPO4x7H2O 10.72 g 
 KH2PO4 2 g 
Dissolve salts in 800 ml MilliQ water and titrate to a pH-value of 7.2 with a saturated 
Na2HPO4x7H2O-solution. Fill to 1 l with MilliQ water. Sterile filtration (Nalgene Filter, 
Nalgene Membrane, 0.22 µm pore width). Store the stock solution at room 
temperature in the cell culture room. 
1x PBS 
Autoclave 450 ml MilliQ water in a 500 ml cell culture bottle. Fill the bottle to 500 ml 
with 50 ml 10xPBS in the hood.  
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100x GPS (Glutamine-Penicillin-Streptomycin) 
 NaCl 80 g 
 Penicillin 1.5 g 
 Streptomycin 2.5 g 
 L-(+)-Glutamine 14.6 g 
Dissolve substances in 500 ml MilliQ water, sterile filtration, aliquot 40 ml in 50 ml 
Falcons. Store at -20°C in the cell culture refrigerator, store at 4°C after thawing. 
 
100x ß-Mercaptoethanol 
 1xPBS 200 ml 
 ß-Mercaptoethanol 144 µl 
Mix solution, sterile filtration and aliquot in 50 ml Falcons. Store at –20°C in the cell 
culture refrigerator, store at 4°C after thawing. 
 
Trypsin 
 NaCl 3.5 g 
 D-Glucose 0.5 g 
 Na2HPO4x7H2O 0.09 g 
 KCl 0.185 g 
 KH2PO4 0.12 g 
 EDTA 0.2 g 
 Trypsin 1.25 g 
 Tris Base 1.5 g 
Dissolve the chemicals in MilliQ water, titrate to pH 7.6 with concentrated HCl, fill to 
500 ml with MilliQ water and sterilize by filtration and aliquot 40 ml in 50 ml Falcons. 
Store at -20°C in the cell culture refrigerator, store at 4°C after thawing. 
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1% gelatine stock solution 
Solve 100 g gelatine (Difco) in 1 l MilliQ water. Sterilize by filtration. Store at room 
temperature in cell culture. 
0.1% gelatine solution 
Autoclave 450 ml of Milli-Q water in a cell culture bottle and add 50 ml of the 1% stock 
solution in the hood and mix. 
Dulbeccos modified eagles medium (DMEM) 
To prepare DMEM a 5 l Erlenmeyer is filled with 4.5 l Milli-Q water. Exactly one half of 
a 10 l DMEM package (Gibco) is added under stirring. Upon dissolution of the powder 
18.5 g of sodium bicarbonate is added. The Erlenmeyer is filled to 5 l and the medium 
is filtered through sterile filters into autoclaved bottles. 4 ml of medium per bottle is 
left aside and incubated at 37°C over night. The medium is analyzed for 
contaminations under the microscope the next day.  
 
3.6 Nutrition media for cell culture 
M10Gi:  for fibroblasts: 
 DMEM 
 10% Fetal bovine serum from Gibco 
 1x GPS 
M15Hi:  for ESC and CVPC: 
 15% = 30 ml Fetal bovine serum from HyClone 
 1% = 2 ml GPS 
 1% = 2 ml ß-Mercaptoethanol 
          To 200 ml with DMEM 
M15Si:  for CBs: 
 15% = 60 ml Fetal bovine serum from Sigma 
 1% = 4 ml GPS 
 1% = 4 ml ß-Mercaptoethanol 
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           To 400 ml with DMEM 
Freezing medium: 
 60% DMEM 
20% FBS (Gibco for fibroblasts, HyClone for ES cells) 
 20% DMSO 
 Note: Always add DMEM first; when mixed use it immediately afterwards 
 
3.7 Media and solutions for insect cell culture 
SF9 thawing and adaptation medium: 
Same as culture medium, only with 20-5% FCS 
 
SF9 culture medium:                                        Infection medium: 
Sf-900 medium                                                Sf-900 medium 
2% FBS                                                               2% FBS 
1% P/S 
 
SF9 freezing medium:                                     Baculovirus freezing medium: 
20% FBS                                                        Add 4% FBS to CM containing viral particles 
20% DMSO 
60% Sf-900 medium 
 
3.7.1 Coating of cell culture plates 
Cell culture plates have to be gelled to serve as a matrix for the cells to adhere. Apply 
at least 2 ml of 0.1% gelatine solution per 6-well and 6 cm plate, or 3 ml per 10 cm. 
Leave gelatine solution on plates for two hours at room temperature, then suck off the 
solution completely with a Pasteur pipette. Use the cell culture plates directly after 
gelling. 
28 
 
3.7.2 Maintenance of SNL67/7 
SNL67/7 fibroblast feeder cells express LIF (Leukemia inhibitory factor). 
3.7.3 Thawing of SNL76/7 
10 cm culture plates must be coated with gelatine before starting the defrosting 
procedure. SNL67/7 are stored in cryotubes at 180°C in liquid nitrogen. Cryotubes are 
carefully removed from liquid nitrogen tank and defrosted in a 37° bath until a thin 
icicle is left in the tube. Cryotubes are disinfected with 70% EtOH, dried, placed in the 
laminar flow and flamed before and after opening. The content (1.8 ml) is transferred 
into a 15 ml falcon tube and 10 ml M10Gi are added drop by drop while mixing over a 
time period of at least 5 minutesto prevent an osmotic shock. 15 ml Falcons are 
centrifuged at 1000 rpm for 7 minutes at room temperature (Heraeus, Biofuge). After 
the supernatant is discarded pellets are resuspended in 1 ml of M10Gi. Another 3 ml of 
M10Gi is added to 15 ml Falcons and then transferred onto a gelatin coated 10 cm 
culture dish. Falcons are washed with 4 ml of fresh M10Gi and the solution is added to 
the culture dish.  
3.7.4 Cultivation of SNL76/7 
SNL67/7 cells are cultured at 37°C and 5% CO2. Medium must be replaced by fresh 
M10Gi if color switches to orange or yellow. Cells must be split when plate is 
confluent.  
3.7.5 Splitting of SNL76/7 
When confluent, cells must be split onto new gelatin coated culture dishes. Medium is 
discarded and plates are washed with 1xPBS. PBS is applied to remove leftover of 
M10Gi that would inhibit function of trypsin. After PBS is sucked off 1 ml of trypsin is 
evenly applied to the culture plate and plates are incubated at 37°C and 5% CO2 for 5 
minutes.3 ml of fresh M10Gi are added to culture plates to stop trypsin. Cells are 
resuspended and 500 µl solution are transferred onto gel coated culture plates 
containing 7 ml of fresh M10Gi (for splitting of 1:8), (1:5 splitting: add 4 ml to 
trypsinized cells and transfer 1 ml). 
3.7.6 Freezing of SNL76/7 
When SNL76/7 are confluent they can be frozen. Therefore culture medium is 
discarded and cells are washed with 1x PBS. After removal of PBS 0.7 ml trypsin is 
added to a 10 cm culture dish and placed into incubator (37°C; 5%) for 10 minutes. 
Trypsinized cells are resuspended in 2 ml of M10Gi and transferred to a 15 ml falcon 
tube. 2.7 ml of freezing medium (with Gi Serum) are added drop by drop to the 
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suspension. This should be done very slowly. The content is divided into two cryotubes 
and placed in a Styrofoam box which is then sealed with tape and placed into a –80°C 
freezer. After two days cryotubes can be moved to a nitrogen tank (-196°C). 
Freezing medium:  
60% DMEM 
20% Gibco Serum 
20% DMSO 
3.7.7 Preparing feeder cells 
All culture dishes must be gelatin-coated before usage. Confluent SNL76/7 plates can 
be used to make feeder cells. For this purpose, all medium is discarded except 4 ml and 
80 µl mitomycin C is added to the culture dishes. After a maximum of 4 hours at 37°C 
and 5% CO2, the supernatant is removed and plates are washed twice with 1xPBS. 1 ml 
of trypsin is added to each plate and placed at 37° and 5% CO2 for 5 minutes or until 
cells are floating around. Cells are resuspended in 5 ml of M10Gi (if more than one 
plate was trypsinized cells can be pooled with a maximum of three plates) and solution 
is transferred into a 45 ml falcon. In order to transfer a maximum of cells, plates are 
washed with additional 10 ml M10Gi. The falcon containing 15 ml cell suspension is 
centrifuged at 1000 rpm for 7 minutes (Heraeus) and supernatant is discarded. Pellet is 
resuspended in 1 ml of M10Gi and another 9 ml of M10Gi is added. 50 µl of suspension 
is added to 10 ml of CASY tone solution and measured with a CASY cell counter (10 
µm-30 µm). Cells are diluted till viable cell number reaches 3.5x10
6
. For 24-well plates 
pipette 0.5 ml/well, for 6-well plates 2 ml/well, and for 6 cm plates use 4ml of 
suspension. 24-well plates should not be moved too much after pipetting and are 
directly placed into incubator whilst all other plates should be moved up and down for 
an equal distribution of feeder cells in the well. Feeder cells can be kept in an 
incubator (37°C; 5%CO2) for up to two weeks and have to be fed at least once a week 
with M10Gi. Do not use feeder cells that are older than two weeks.  
3.7.8 Maintenance of mouse embryonic stem cells (mESCs) 
To keep mouse embryonic stem cells undifferentiated they are co-cultured with feeder 
cells which express leukemia inhibitory factor (LIF). 
3.7.9 Thawing of mESCs 
Defrosting of ESCs is quite similar to defrosting SNL76/7. Feeder cells must be fed with 
M10Hi at least 2 hours prior to thawing of mESCs. Cryotubes are removed from liquid 
nitrogen tank and thawed in a 37°C water bath until only a small icicle is left and are 
then disinfected with 70% EtOH. The content is transferred to 15 ml falcon tubes and 
12 ml of M15Hy are added drop by drop. This should be done slowly and tubes should 
30 
 
be pivoted after every drop. After the first 5 ml are successfully added, pipetting speed 
can be enhanced to two drops at a time. Tubes are centrifuged at 1000 rpm for 6 
minutes and supernatant is sucked off. Cell pellets are resuspended in 1 ml of pre-fed 
feeder cell supernatant and then transferred back onto feeder cells. To ensure transfer 
of as many cells as possible wash tubes with another 500 µl of fresh M15Hy. Cell 
density might be low at first since some cells die during this procedure. 
3.7.10 Cultivation of mESCs 
ESCs are cultivated at 37°C and 5% CO2. Medium must be replaced by fresh M15Hy if 
color switches to orange or yellow. Cells must be split when plate is confluent.  
3.7.11 Splitting of ESCs 
Feeder cells and ESCs must be fed with fresh M15Hy two hours prior to splitting 
(feeders 2 ml, ESC 0.5 ml). Medium of the ESCs is sucked off and cells are washed with 
1xPBS once. After removal of PBS trypsin is applied to plates (200 µl/24-well; 500 µl/6-
well; 1 ml/10 cm) and plates are placed at 37°C and 5% CO2 for 15 to 20 minutes or till 
cell adhesion is lost. In case of 24-wells 1 ml of M15Hy medium (for all other wells at 
least thrice the amount of trypsin used) from previously fed feeder cells is transferred 
onto ESCs and resuspended well. For splitting 1:2 600 µl of suspension are transferred 
back onto feeder cells (1:3 400 µl). Plates are cultured at 37°C and 5% CO2. 
3.7.12 Freezing of mESCs 
Cells are fed 2 hours prior to freezing. Cells are washed with PBS and trypsinized (200 
µl/24-well) and after 15 minutes at 37°C and 5% CO2 800 µl fresh M15Hy are added to 
24-wells. Cells are resuspended and transferred into 15 ml falcons. 1.8 ml freezing 
medium is slowly added drop by drop to falcons, after every drop Falcons must be 
shaken slightly to assure homogenous distribution. After addition suspension is divided 
into two cryotubes, these are labeled and placed into a Styrofoam box, which is then 
sealed and put at -80°C for at least two days before transfer of cryotubes into liquid 
nitrogen tank.  
Freezing medium:  
60% DMEM 
20% HyClone Serum 
20% DMSO 
3.8 Maintenance of CVPCs 
CVPCs are maintained undifferentiated like mESCs on a feeder cell layer of LIF 
expressing SNL 76/7.  
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3.8.1 Thawing of CVPCs 
CVPCs are thawed exactly as mESCs. 
3.8.2 Cultivation of CVPCs 
ESCs are cultivated exactly as mESCs. 
3.8.3 Splitting of CVPCs 
Feeder cells and CVPCs must be fed with fresh M15Hy two hours prior to splitting 
(feeders 2 ml, ESC 0.5 ml). Medium of the ESCs is sucked off and cells are washed with 
1xPBS once. After removal of PBS trypsin is applied to plates (200 µl/24-well; 500 µl/6-
well; 1 ml/10 cm) and plates are placed at 37°C and 5% CO2 for 10 to 15 minutes or till 
cell adhesion is lost. In case of 24-wells 1 ml of M15Hy medium (for all other wells at 
least thrice the amount of trypsin used) from previously fed feeder cells is transferred 
onto ESCs and resuspended well. For splitting 1:2 600 µl of suspension are transferred 
back onto feeder cells (1:3 400 µl). Plates are cultured at 37°C and 5% CO2. 
3.8.4 Freezing of mESCs 
Cells are fed 2 hours prior to freezing. Cells are washed with PBS and trypsinized (200 
µl/24-well) and after 10 to 15 minutes at 37°C and 5% CO2 800 µl fresh M15Hy are 
added to 24-wells. Cells are resuspended and transferred into 15 ml Falcons. 1.8 ml 
freezing medium is slowly added drop by drop to falcons, after every drop Falcons 
must be shaken slightly to assure homogenous distribution. After addition suspension 
is divided into two cryotubes, these are labeled and placed into a Styrofoam box, 
which is then sealed and placed at -80°C for at least two days before transfer of 
cryotubes into liquid nitrogen tank.  
 
3.9 Embryoid bodies 
3.9.1 Making embryoid bodies 
24 hours before making EBs mESCs cultured on feeder cells in 24-wells must be split at 
a ratio of 1:2 because mESCs should be in the log phase of proliferation. Cells are fed 2 
hours prior with M15Si and 6-well plates should be coated with gelatine. After 2 hours 
the medium is discarded and the cells are washed with 1xPBS and 200 µl of trypsin is 
added to the cells. Plates are incubated at 37°C and 5%CO2 until cells dissociate. 800 µl 
of M15Si are added to stop the reaction and suspension is transferred onto gelatin 
coated 6-well plates containing 2 ml of M15Si in order to separate stem cells from 
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feeder cells. Feeder cells adhere faster to the gelatine surface of the 6-well plates 
whereas embryonic stem cells remain nonattached for a longer time period. After 50 
minutes of incubation at 37°Cand 5% CO2, supernatant is transferred into a 15 ml 
falcon. In order to make sure most embryonic stem cells are transferred, 1 ml of M15Si 
is trickled onto 6-well plates and then transferred to the falcon. Suspension is filled up 
to 10 ml total volume and 20 µl are transferred into a CASY tube containing 10 ml of 
CASY ton. The cell number is determined using CASY counter. Suspension is diluted 
with M15Si to a cell concentration of 4x10
4
 cells/ml. 2 ml of this dilution is sufficient 
for one 10 cm dish of hanging drops.  
Sterile culture plates are filled with autoclaved Milli-Q water (a 4mm high water level is 
enough). 4 ml of cell suspension is transferred into a 6 cm plate. A multi-pipette is set 
so that 20 µl (equals 800 cells per drop) are dispensed each time. The pipette is loaded 
and held at a 90° angle to the lid of the culture plate. Drops are placed as close as 
possible without mixing. Flip lid over and place on top of water filled bottom half. Place 
carefully at 37°C and 5%CO2. This time point is referred to as day 0. At day 4.7 the 
hanging drop cultures have to be transferred onto gelatine coated 10 cm tissue culture 
plates to allow attachment of the EBs to the culture dishes. 10 cm petri dishes are 
coated with gelatine 2hours prior to use. Hanging drop cultures are taken out of 
incubator and 8 ml of M15Si are used to rinse the embryoid bodies from the lid of the 
culture dish onto the bottom of the petri dish plate. Place dishes at 37°C and 5% CO2 
and do not move for 24hours. 
3.9.2 Culture of embryoid bodies 
Embryoid bodies must be fed every 3 days with M15Si, medium is only partially 
replaced (day 7 and 10: 3ml of old medium+5 ml fresh; day 13 to 24: 4 ml old+10 ml 
fresh, day 25 and thereafter: 5 ml old+12 ml fresh). Partial medium replacement 
ensures that secreted factors remain in medium at low concentration. 
3.9.3 SF9 cell culture 
The SF9 cell line was derived from pupal ovarian tissue of the fall armyworm 
Spodoptera frugiperda. The SF9 cell line is highly susceptible to infection with 
Autographa California nuclear polyhedrosis virus (AcNPV baculovirus), and can be used 
with all baculovirus expression vectors. SF9 cells are commonly used to isolate and 
propagate recombinant baculoviral stocks and to produce recombinant proteins. 
3.9.4 Thawing and adaptation of SF9 cells 
SF9 cells are kept in liquid nitrogen for storage and stock purposes. 
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The cells are quickly thawed and resuspended in SF9 II medium supplemented with 
20% serum (Gibco), centrifugated at 1000 rpm for 5 minutes. The resulting pellet is 
resuspended in 5 ml of 20% serum containing medium again, and the cells are 
transferred to a 50 ml culture flask. The cells are kept in sealed flasks at 28°C. 
Once the culture has reached confluence, cells are gently scraped off the surface, 
collected and centrifugated at 1000 rpm for 5 minutes. The pellet is then resuspended 
in medium containing 15% serum, and the cells are seeded on a 50 ml culture flask. 
This procedure is repeated with serum content decreasing by 5% every time the cells 
are split. When the serum content is below 5%, usually 2% serum is used for 
maintenance of the cells. 
3.9.5 Storage of SF9 cells 
For storage, SF9 cells are collected and resuspended in medium containing 20% serum, 
equal amounts of freezing medium (containing 20% serum and 20% DMSO) are added 
drop by drop, and the cells are stored in cryo tubes at -80°C for 24 hours. After that 
they can be transferred to liquid nitrogen. 
3.9.6 Infection of SF9 cells 
For expression of the desired isoforms of LIF, the cells are seeded at a correct cell 
number required for infection (4 x 10
7
 per flask in 20 ml medium) and the virus is 
added according to the desired MOI. Infection is achieved after 96 hours, upon which 
the cells are visibly bloated and cell lysis sets in. 
3.9.7 Protein purification from SF9 cells 
After infection, the cells are collected by centrifugation for 5 minutes at 1000 rpm. The 
supernatant is removed, 5 ml of 1xPBS are added, and the cells are collected by 
centrifugation for 3 minutes at 1000 rpm. The 1xPBS is discarded and the cells are 
frozen at -80°C until further use.  
The cell pellet is thawed on ice and resuspended in freshly prepared lysis buffer. This is 
followed by incubation on ice for 15 minutes. The cell lysate is then mechanically 
disrupted on ice in a douncer, after which it is incubated on ice for 10 minutes. The 
lysate is then cleared by centrifugation at 14000 rpm and 4°C for 20 minutes. 
Thereafter, 10 µl of the supernatant are taken for analysis and the rest is distributed 
equally amongst four 2 ml Eppendorf tubes containing 200 µl of Ni-NTA 
(nitrilotriacetic) agarose beads (Quiagen) each, which have been equilibrated in lysis 
buffer. The beads are then rotated at 4°C for 2.5 hours. 
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After loading, the beads are pelleted at 4°C, 14 000 rpm for 5 minutes. The beads are 
washed three times with 500 µl of freshly prepared wash buffer by inverting the tube 
several times and subsequent pelleting of the beads at 4°C, 14 000 rpm for 5 minutes. 
 
Elution fractions E1 and E2 are obtained by adding 200 µl of freshly prepared elution 
buffer I, followed by shaking at 800 rpm for 10 minutes and subsequent pelleting of 
the beads at 4°C, 14 000 rpm for 5 minutes, after which the supernatant is collected. 
Elution fractions E3 and E4 are obtained by adding 200 µl of freshly prepared elution 
buffer II, followed by shaking at 800 rpm for 10 minutes and subsequent pelleting of 
the beads at 4°C, 14 000 rpm for 5 minutes, after which the supernatant is collected. 
The purified protein is stored at 4°C and analyzed on an SDS polyacrylamide gel. 
 
Lysis buffer                         Wash buffer 
50 mM NaH2PO4               50 mM NaH2PO4 
300 mM NaCl                 300 mM NaCl 
10 mM Imidazole                                                                 10 mM Imidazole 
adjust pH to 8 using 1 M NaOH                                          adjust pH to 8 using 1 M NaOH 
add NP-40 at a dilution of 1:100 directly before use 
Elution buffer I              Elution buffer II 
50 mM NaH2PO4             50 mM NaH2PO4 
300 mM NaCl               300 mM NaCl 
50 mM Imidazole                                                                  250 mM Imidazole 
Adjust pH to 8 using 1M NaOH                                            adjust pH to 8 using 1M NaOH 
All reagents used in protein purification contain protease inhibitors Aprotinin, 
Leupeptin, and Pepstatin A at a dilution of 1:1000. 
If the protein is to be used for activity assays in cell culture, the sample must be freed 
from salts and imidazole prior to use. This is achieved by dialysing against a semi-
permeable membrane as follows: 
Preparation of dialysis membrane: 
1. 15 cm of a regenerated cellulose tubular membrane (Roth) are rinsed with 
distilled water. 
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2. The membrane is placed into a 50 ml Falcon tube containing 50 ml of Solution 1 
and heated in a waterbath at 60°C for 3 hours (this removes any traces of heavy 
metal ions). 
3. The membrane is rinsed again with distilled water. 
 
 
Preparation of Eppendorf tubes: 
4. Holes are burnt into the lids of Eppendorf tubes with a heated Pasteur pipette. 
5. 400 µl of sample are added per tube. 
 
Dialysis: 
6. Pieces of the membrane (~2 cm) are cut off and clamped underneath the lids of 
the prepared Eppendorf tubes, thereby covering the holes. The rest of the 
membrane is stored in 40% Ethanol. 
7. The tubes are centrifuged upside down at 1000 rpm for 1 minute to test for 
leakage. 
8. If no leakage is visible, the tubes are placed upside down into a beaker 
containing 1xPBS at a concentration of 1:1000 in relation to the sample 
amount. Otherwise, repeat step 7. 
9. The beaker is left over night at 4°C, stirring. 
 
Solution 1: 
1 mM EDTA 
2% Sodiumhydrogencarbonate 
After dialysis, concentration and purity of the protein are measured with the 
Nanodrop device. 
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3.10 SDS Polyacrylamide gel 
Isolated proteins are treated with 3x Sample buffer and separated on a denaturing 
SDS-polyacrylamide gel. 
3x Sample buffer: 
3 ml Glycerin 
0.9 g SDS 
3.75 ml of Solution 7  
1.75 ml ddH2O 
6 mg Bromphenolblue 
• aliquot and store at -20°C 
• add 150 µl β−Mercaptoethanol for 850 µl sample buffer aliquot before use 
 
SDS polyacrylamide gel 
 
 
 
 
 
 
 
 
 
Table 1: Reagents for one mini-protean gel (Biorad). 
 
Solution 7: 
1.5 M Tris/Cl pH 8.8 (18.17 g Tris)  
0.4% SDS (4 ml 10% SDS) 
H2O to 100 ml 
Solution 15% 12% 9% 6% Stack 
9 5 ml 4 ml 3 ml 2 ml 250 µl 
7 2.5 ml 2.5 ml 2.5 ml 2.5 ml - 
8 - - - - 600 µl 
H2O 2.45 ml 3.45 ml 4.45 ml 5.45 ml 1.59 ml 
TEMED 5 µl 5 µl 5 µl 5 µl 5 µl 
10% APS 50 µl 50 µl 50 µl 50 µl 25 µl 
Solution 8: 
0.5 M Tris/Cl pH 6.8 (6.06 g Tris) 
0.4% SDS (4 ml 10% SDS) 
H2O to 100 ml 
Adjust pH to 6.8 
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Adjust pH to 8.8 
Solution 9: 
30% Acrylamide (30g Acrylamide) 
0.8% Bis N,N’-Methylenbisacrylamide (0.8 g Bis N,N’-Methylenbisacrylamide) 
H2O to 100 ml 
 
 
 
10x Running buffer: 
30g Tris 
144g Glycine 
10g SDS 
H2O to 1l 
Running conditions: 
After polymerization of the gel, proteins and a size marker (BioRad low range or high 
range ladder) are loaded and run in a BioRad Mini Protean Gel chamber, in 1x running 
buffer, with 25 mA for the first 15 minutes and then 50 mA for 1-2 hours, depending 
on the percentage of the gel.  
3.11 Coomassie staining 
SDS polyacrylamide can be analyzed by staining with Coomassie brilliant blue for 30 
minutes, followed by incubation with destaining solution over night.  
Preparative gels for Mass Spectrometry analysis must be stained with fresh Coomassie 
staining solution in a glass container. Gel pieces are excised using sterile scalpels 
(Swann Morton) in a laminar flow hood. 
Coomassie brilliant blue      Destain 
45% (v/v) Methanol       4.5% (v/v) Methanol 
10% (v/v) Acetic acid                  10% (v/v) Acetic acid 
0.4% (w/v) Coomassie Brilliant Blue 
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3.12 Western blot analysis 
Proteins separated by a denaturing SDS-polyacrylamide gel are transferred to a 
nitrocellulose membrane (Schleicher and Schuell) using a Biorad semi-dry transfer cell. 
The blot consists from the bottom upwards of: 6 layers of whatman paper the same 
size as the gel, one nitrocellulose membrane the same size as the gel, the gel and 6 
layers of whatman-paper the same size as the gel. All components are soaked with 
blotting buffer.  
Air bubbles are removed by applying pressure with a Falcon tube. Blotting is carried 
out at 16 V for 1 hour in a Biorad semi-dry transfer cell. 
 
10x Blotting buffer: 
0.48 M Tris  
0.4 M Glycine 
ddH20 
Adjust pH to 9.1 
After blotting the protein is stained with Ponceau-S for 5 minutes and rinsed with 
water to assess transfer and to visualize the protein ladder, which can then be marked 
with a pen. 
Ponceau-S         
100 mg Ponceau-S        
100 ml 1% glacial acetic acid   
  
Antibody incubation and development of the blot: 
After blotting, the membrane is blocked with blocking solution for 1 hour. This is 
followed by three wash steps with 1xTBS/0.1% Tween for 5 minutes each and 
incubation over night with primary antibody solution. On the following day, the 
membrane is washed three times with 1xTBS/0.1% Tween for 5 minutes each and 
incubated with the secondary antibody solution for 1 hour. The membrane is then 
washed three times with 1xTBS/0.1% Tween for 5 minutes each. 
• for an AP conjugated antibody the blot is incubated with AP buffer for 5 
minutes 
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• the blot is incubated with 10 ml of AP buffer with 33 µl of NBT (added 
first) and 66 µl of BCIP (add second) 
• the blot is incubated in the dark until bands become visible (5-60 
minutes), the reaction is  stopped by removing AP buffer and washing 
with water 
 
 
Blocking solution: 
5% dry milk powder (low fat) 
dissolve in 1xTBS/0.1% Tween 
 
Primary antibody  solution                     Secondary antibody  solution 
5% BSA                                                                   5% dry milk powder (low fat) 
dissolve in 1xTBS/0.1% Tween                              dissolve in 1xTBS/0.1% Tween                                                                    
desired amount of primary antibody                    desired amount of secondary antibody 
 
NBT 
75 mg NBT 
700 µl Dimethylformamid 
300 µl H2O 
 
BCIP 
50 mg BCIP  
1 ml Dimethylformamid 
 
 
 
AP Buffer: 
100 mM Tris/Cl pH 9.5 
100 mM NaCl 
50 mM MgCl2 
 
ECL stock solution: 
Dilute 20 ml 1MTris in 200 ml H2O 
Add 0.5 ml p-Coumaric acid 
Add 1 ml Luminol 
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Primary antibody Secondary antibody 
α LIF 1:500 anti goat AP 1:10 000 
Table 2: Antibodies used for Western blotting. 
 
3.13 Immunofluorescence 
Let cells or CBs grow on gelatin coated coverslips in cell culture plates until a proper 
cell density is reached. 
 
Fixation of cells on coverslips 
• Wash cells twice with PBS 
• Slowly add EtOH (-20°C) drop wise  
• Store cover slips 20’ at -20°C in EtOH 
• Add 800 µl dH2O (4°C) until an EtOH concentration of 70% is reached. 
• Store 10’ at -20°C 
• Cells can now be used for immunostaining or can be stored at 4°C. Cover plates 
with parafilm. 
 
3.14 Immunostaining: 
• Suck off EtOH solution and wash 3x 5’ with PBS.  
• Dilute primary antibody in PBS during washing steps. 
• Drop 100 µl primary antibody solution on the lid of a 6 well culture 
plate.  
• Take the coverslip out of the washing solution with a forceps and place 
it upside down on the antibody drop. 
• Give wet tissues into the bottom wells of the 6 well plateand put it over 
the lid.  
• Incubate the 6-well plate for 1,5 hours in a wet chamber. 
• Remove the coverslips from the lids and wash it 3x 5’ with 2 ml PBS in 6-
well-plate wells. 
• Dilute secondary antibody during washing in PBS. 
• Drop 100 µl of the secondary antibody dilution on the lid of a 6-well 
plate and place the coverslips upside down onto the drops. 
• Incubate for 45’ in a wet chamber.  
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• Wash 1x 10’ with 2 ml PBS and a according to instruction manual 
concentration of DAPI (4',6-diamidino-2-phenylindole). 
• Wash 2x 10 min with 2 ml PBS. 
• Preheat mowiol to 50°C during washing. 
• Cut of a yellow 200 µl Gilson pipette tip and pipette 40 µl mowiol onto a 
glass slide. 
• Put the cover slips upside down onto the mowiol drops. 
• Let the preparation dry over night. 
• Seal the edges of the coverslips with non-fluorescing nail polish. 
 
 
 
Primary antibody Secondary antibody 
α cTnT 1:100 α goat FITC Ab 1:200 
α SPARC 1:50 α rabbit TR 1:200 
Table 4: Antibodies used for Immunostaining. 
 
3.15 Confocal laser scanning microscope (CLSM) 
In contrast to conventional wide field fluorescence microscopes confocal laser 
scanning microscopes produce images which are focused on an optical plane with 
selectable depth.  
Zeiss LSM 510 META confocal microscope: 
After switching on the UV lamp, the microscope, the lasers and the computer the Zeiss 
LSM 510 META software has to be started. First the correct excitation light wave length 
and the light emission filters like FITC/TRITC have to be chosen. Switch on UV light and 
focus on DAPI stained nuclei to find the correct optical plane. Switch from visual mode 
to computer mode. 
Step by step manual: 
• Start software LSM 510 META in expert mode. 
• Go to “Aquire/Lasers” and turn on required Lasers. 
• Put a drop of oil on the cover slip. 
• Go to “Aquire/VIS” to activate visual mode. 
• Switch “FL on/off” button on and turn on UV-light. Focus on the correct plane 
by focusing on e.g. DAPI stained nuclei. 
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• Go to “Aquire/LSM/Scan” for scanning an image. 
• In the scan control window choose “Fast XY” to adjust the laser intensity while 
the image is updated every few seconds. 
• After adjustment of the laser intensity choose “Stop/Single” for scanning of a 
high resolution image. 
• Go to “File/Save” as to save the image. 
• The format of the pictures is “.lsm” and they can only be opened with the LSM 
510META program. For conversion to a different file format choose 
“Export/tif”. 
3.16 Reverse transcriptase polymerase chain reaction 
3.16.1 Isolation of mRNA with RNAeasy Mini KIT (Qiagen): 
At least 1 confluent plate of a 24-well plate of CVPCs or mESCs is necessary for RNA 
isolation. 
• Suck off medium and wash cells 2x with PBS.  
• Add 1ml PBS and scrape off cells.  
• Centrifuge 5’ at 13.000 rpm with Eppendorf 5415C. 
• Discard supernatant and resuspend pellet in 600 µl RLT buffer containing 6 
µl ß-mercaptoethanol. 
• Load lysate onto Qia-shredder column and homogenize at 13.000 rpm. 
• Mix lysate with 600 µl 70% RNase free EtOH. 
• Load 600 µl of lysate onto RNeasy mini columns, put columns into a 2 ml 
tube and spin at 13.000 rpm for 15’’. 
• Discard flow-through and load remaining 600 µl of lysate. 
• Wash columns with 350 µl RW1, 15’’, 13.000 rpm. 
• Wash columns 2x with 500 µl RPE 
• Dry spin columns in empty 2 ml tubes. 
• Put columns into 1,5 ml eppendorf tubes. 
• Elute RNA with 40 µl RNase free water. 
• Spin 1’, 13.000 rpm. 
• Mix 30 µl RNA solution 3.75 µl DNase Buffer and 3.75 µl DNase I. Digest 
DNA for 30’ at 37°C. 
• Stop digestion by adding 3.75 µl stop buffer (EDTA), 10’ 65°C. Take 1 µl for 
agarose gel. Store RNA at -80°C. 
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3.16.2 Reverse transcription: 
• Prepare RT-Mix: 60 µl 5x buffer, 30 µl 0,1MDTT, 9 µl RNAsin (RNase out, or 
Ribolock), 12 µl 10 mM dNTPs. 
• Add 1 µl oligo dT. 
• Incubate 10’, 70°C. 
• Leave 3’ on ice. 
• Spin 15’’, 13.000 rpm. 
• Add 18,5 µl RT-Mix 
• Incubate 2’ at 42°C 
• Add 1 µl reverse transcriptase and incubate 50’ at 42°C. 
• Stop reaction with 15’ at 70°C. 
• Put 5’ on ice. 
• Centrifuge 2’ at 13.000 rpm. 
• Store cDNA at -80°C. 
3.16.3 Polymerase chain reaction: 
• PCR standard reaction mix :  
1 µl cDNA 
5 µl 10x PCR buffer 
1.5 µl 50 mM MgCl2 
1 µl 10 mM dNTPs 
0.5 µl forward primer (100pmol/µl) 
0.5 µl reverse primer (100pmol/µl) 
0.25 µl taq polymerase (1.25 U) 
40.25 µl ddH2O 
Standard PCR-program: 
Step Temperature Time 
1 94°C 1 min 
2 94°C 45 sec 
3 Annealing temperature 45 sec 
4 72°C 1 min 
5 72°C 5 min 
6 4°C infinite 
 
29 to 35 cycles between step 2 and step 4 were used depending on PCR efficiency. 
 
Used Primer and annealing temperature: 
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Gene   Primer sequence 
Annealing 
temp. 
Cycles  PCR product 
BMP2 
Fwd 5‘ – GTTTGTGTTTGGCTTGACGC – 3‘ 
57.5°C 34 
cDNA 719bp 
Rev 5‘ – AGACGTCCTCAGCGAATTTG – 3‘   
Desmin 
Fwd 5’ – TGACAACCTGATAGACGA – 3’ 
50°C 37 
cDNA 390bp 
Rev 5’ – TTCTTATTGGCTGCCTGA – 3’ Genomic  1972bp 
Gata4 
Fwd 5’ – GCCTGTATGTAATGCCTGCG – 3’ 
53°C 31 
cDNA 500bp 
Rev 5’ – CCGAGCAGGAATTTGAAGAGG – 3’ Genomic 3364bp 
GAPDH 
Fwd 5’ – CGTCTTCACCACCATGGAGA – 3’ 
55°C 29 
cDNA 300bp 
Rev 5’ – CGGCCATCACGCCACAGTTT – 3’ Genomic 300bp 
Mef2C 
Fwd 5’–GGCCATGGTACACCGAGTACAACGAGC-3’ 
66°C 34 
cDNA 395bp 
Rev 5’ –GGGGATCCCTGTGTTACCTGCACTTGG-3’   
Mesp1 
Fwd 5’ – AGAAACAGCATCCCAGGAAA – 3’ 
52°C 32 
cDNA 346bp 
Rev 5‘ – GTGCCTGCTTCATCTTTA – 3’ Genomic 619bp 
Nanog 
Fwd 5’ – AGGGTCTGCTACTGAGATGCTCTG – 3’ 
60°C 25 
cDNA 364bp 
Rev 5’ – CAACCACTGGTTTTTCTGCCACCG – 3’ Genomic 4793bp 
Oct 3/4 
Fwd 5’ – CCACCTTCCCCATGGCTGGACA – 3’ 50°C 37 cDNA 1082bp 
Rev 5’ – AGGGCTGGTGCCTCAGTTTG – 3’   Genomic 4475bp 
Tropo-
myosin α 
Fwd 5’ – CAAGCGGAGGCTGATAAGAAGG – 3’ 
55°C 30 
cDNA 310bp 
Rev 5’ – TGCCTCTCTCACTCTCATCTGC – 3’   
Nkx2.5 Fwd 5’ – CACCCACGCCTTTCTCAGTC - 3’ 57°C 40 cDNA 513bp 
 Rev 5’ – TGGACGTGAGCTTGAGCA - 3’     
Sox2 Fwd 5’ – AACCCCAAGATGCACAACTC – 3’ 55°C 34 cDNA 202bp 
 Rev 5’ – CTCCGGGAAGCGTGTACTTA – 3’     
SPARC Fwd 5’ – GTCCCACACTGAGCTGGC – 3’ 55°C  cDNA 590bp 
 Rev 5’ – AAGCACAGAGTCTGGGTGAGTT– 3’     
Table 5: Primer and annealing temperature:  
Fwd: Forward Primer 
Rev: Reverse Primer 
cDNA: Sequence of mRNA pCR product 
Genomic: Sequence of gemonic DNA PCR product 
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3.16.4 Agarose gel 
1% Agarose gels were used for analysis of PCR products. Agarose gels were stained 
with ethidiumbromide for 20 min to visualize DNA fragments.  
100 ml 1% agarose gel: 1g agarose, 100 ml dH2O 
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4 Results: 
4.1 CVPCs autonomously differentiate to cardio-vascular cells in 
hanging drop culture 
Analogous to ESCs CVPCs were maintained undifferentiated by cultivation on LIF 
expressing SNL76/7 feeder cells. 3 CVPC clonal cell lines (B5, G3 and H3) cultivated on 
feeder cells were trypsinized and transferred to gelatin coated 6 cm cell culture plates 
for pre-adsorption of the co-cultivated fibroblast feeder cells. Fibroblasts can thereby 
be removed because they adhere faster than CVPCs to the gelatin coated matrix of cell 
culture plates. After 50 minutes the supernatant containing solely CVPCs was taken off. 
50 20 µl drops containing 800 CVPCs each were placed onto the lid of a 10 cm culture 
plate. 3 lids with 50 hanging drops each were established per clone. Cardiac bodies 
were observed daily by phase contrast microscopy (Figure 1). 
 
 
Figure 1: Cardiac body consisting of 800 CVPCs clone H3 24 hours after preparation inside a hanging droplet: The 
CVPCs assembled at the lowest point of the drop and started to aggregate. Bar=100 µm. 
 
The lids with the hanging droplets were carefully put onto sterile plates filled with 
autoclaved double-distilled water and incubated at 37°C for 4 days. The cells in the 
drops formed a compact sphere which was named ‘cardiac body’ (CB) because of the 
morphological and methodical similarity to embryoid bodies (Figure 2). At day 4 the 
cardiac bodies were rinsed off into a gelatin coated 10 cm cell culture plate.  
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Figure 2: Cardiac body of CVPC clone H3 at day 5 after transfer to a cell culture plate: A compact sphere has 
formed which will adhere to the gelatin coated plate surface. Bar=100 µm. 
 
Cardiac Bodies adhered to the gelatin coated surface of the cell culture plates within 
24 hours. The CBs started to spread and cell divisions and growth of the CBs was 
observed. Cysts developed after day 6 which were apparent in sporadic non-adhered 
swimming CBs as bubbles. Monolayers of endodermal cells were observed in the 
periphery of the CBs. At day 12 beating cardiomyocytes were observed in the center of 
the CBs. Smooth muscle cell contractions were visible at day 15 in B5 and G3 CBs. 
Cardiomyocytes and smooth muscle cells developed into fibers (Figure 3). Beating 
cardiomyocytes and smooth muscle cells were counted daily until day 26. Medium was 
exchanged every third day. 
 
 
Figure 3: Terminal differentiation of Cardiac Bodies: Three different cardiovascular cell types were observed in 
cardiac bodies attached to the plate, contracting smooth muscle cells, contracting cardiomyocytes and endodermal 
cells. Furthermore bubbles of putative vascular endothelial cells were present in all cardiac bodies. Bars=100 µm. 
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All three clones B5, G3 and H3 differentiated into both beating cardiomyocytes (CMCs) 
and contracting smooth muscle cells (SMCs) at a different rate. H3 preferentially 
differentiated into beating cardiomyocytes with 90-100% of observed cardiac bodies 
containing CMCs (Figure 4) between day 16 and 20, whereas B5 developed cardiac 
bodies with 50-100% SMCs (Figure 5) between day 16 and 20.  
 
 
Figure 4: Percentage of cardiac bodies containing beating cardiomyocytes: The percentage of CBs containing 
beating CMCs was determined for CVPC-clone B5 (B5 CBs), G3 (G3 CBs) and H3 (H3 CBs). H3 showed the highest 
percentage of CBS with active CMCs, B5 the lowest. 
 
 
Figure 5: Percentage of cardiac bodies containing contracting smooth muscle cells: The percentage of CBs 
containing beating CMCs was determined for CVPC-clone B5 (B5 CBs), G3 (G3 CBs) and H3 (H3 CBs). B5 showed the 
highest percentage of CBs containing active SMCs, H3 the lowest. 
 
Only cells belonging to the three major types of cardiac cells were apparent: 
cardiomyocytes, vascular endothelial cells and smooth muscle cells. Cells which 
typically arise in embryoid bodies e.g. skeletal muscle cells or neurons were not 
observed indicating that CVPCs have a limited differentiation potential. 
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4.1.1 Activity of CMCs and SMCs in cardiac bodies is antagonistic 
When the activity of CMCs and SMCs was compared it became obvious that the 
activity of SMCs and CMCs is antagonistic (Figure 6A-C). In B5-CBs SMC contractions 
were dominant, whereas in H3-CBs CMC contractions were dominant. In B5-CBs the 
high CMCs activity at day 13 was replaced by the later onset of SMCs activity around 
day 16. In G3-CBs the activity of CMCs was low but increased when SMCs activity 
decreased after day 20. In H3-CBs CMC activity was predominant and less than 10% of 
CBs showed contracting SMCs. 
 
 
 
Figure 6: Comparison of active CMCs to SMCs in CBs: A: CBs of clone B5, B: CBs of clone G3, C: CBs of clone H3. 
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The CBs of all three clones were identical in morphology and CMCs and SMCs were 
both present. The only difference between the clones was the number of contracting 
SMCs and CMCs. High activity of both types of muscle cells at the same time was not 
observed.  
 
4.1.2 Cardiac bodies express cardiac troponin T 
To verify that CMCs in CBs express cardiomyocyte-specific proteins CVPC-clone A5 
cardiac bodies (CB) from day 21 containing beating CMCs were ethanol fixed and 
immune-stained for cardiac troponin T. Troponins form complexes consisting of 3 
proteins called troponin I, troponin C and troponin T which are part of the myofibrils in 
cardiomyocytes. Troponin T binds to tropomyosin, troponin C binds calcium ions and 
cardiac troponin I binds actin. CBs were stained with goat anti-cardiac troponin T 
antibodies (αcTnT) diluted 1:200. FITC-conjugated anti goat antibodies served as a 
secondary antibody. cTnT was present in all examined CBs. cTnT showed the typical 
striated pattern (Figure 7). 
 
 
Figure 7: Immunofluorescence of cTnT in A5-CBs: cTnT (green) staining shows the typical striated pattern in 
myofibrils of cardiomyocytes in A5-CBs at day 21. An oil immersion 63x objective lens was used. Nuclei were stained 
blue by DAPI. 
 
Corresponding to clusters of beating CMCs observed in CBs, clusters of myofibrils 
containing striated cTnT fibers were searched for. Immunofluorescence showed 
expression of cTnT in clusters similar in size to beating CMC clusters observed in CBs 
(Figure 8).  
51 
 
 
Figure 8: Clusters of myofibrils containing cTnT in A5-CBs at day 21: cTnT (green) is present in myofibril-clusters 
corresponding in size to areas of beating CMCs which were observed by phase contrast microscopy in CBs. Nuclei 
were stained blue by DAPI. 
 
4.2 CVPCs autonomously differentiate to cardiomyocytes in vitro 
ESCs readily differentiate to CMCs in EBs, but not when seeded on cell culture plates. 
To examine the differentiation potential of CVPCs in vitro, CVPCs were seeded on 
gelatin coated culture plates at densities ranging from 100.000 to 300.000 cells per 
well in 6-well cell culture plates. Cells were incubated at 37°C and 5% CO2 and the 
medium was exchanged regularly. Active contracting CMCs were observed in all 
experiments and were counted daily (Figure 9, Table 1). In contrast to CBs no smooth 
muscle cells emerged in these experiments. 
 
Figure 9: Beating aggregates of CMCs at different seeding densities: CVPCs were seeded onto a gelatin coated 6-
well plate at different densities 100.000, 110.000 and 300.000 CVPCs per plate respectively. CVPCs differentiated 
and beating aggregates of CMCs were observed and counted daily beginning at day 11. 
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Table 1: Influence of the quantity of seeded cells on the differentiation of CVPCs to 
CMCs  
Experiment Clone 
Seeded 
cells Onset of activity 
Maximal number 
of beating CMCs 
Time of activity  
(Days) 
A H3 100.000 day 11 2339 17 
B H3 110.000 day 13 807 4 
C H3 300.000 day 13 403 9 
H3: CVPC clone H3;   Seeded cells: Seeded CVPCs clone H3 per 6-well culture plate; Maximal number of beating 
CMCs: Highest number of beating CMC aggregates counted on a single day. 
 
In the experimental setup an optimum with a maximal number of CMCs was reached 
when 100.000 CVPCs clone H3 were seeded (table 1, experiment A). A higher quantity 
of active CMCs resulted in longer activity and higher longevity of CMCs. The 
experiment showed that CVPCs have to be seeded sub-confluent at a certain 
concentration on cell culture dishes to efficiently differentiate to beating CMCs. The 
amount of seeded cells influences the differentiation of CVPCs to active CMCs. 
 
4.3 Influence of serum concentration on cardiomyogenesis  
To investigate which effect the fetal bovine serum-concentration in the medium has on 
the differentiation of CVPCs, cells were seeded onto gelatin coated cell culture plates 
and fed with medium containing 5%, 10% and 15% bovine fetal serum, respectively. In 
a small scale experiment after 4 days of cultivation of 300.000 cells of CVPC-clone H3 in 
a 24-well cell culture plate, 8000 cells were seeded into plastic rings containing 300 µl 
medium, 3 rings per gelatin coated 6-well cell culture plate. After 4 days the rings were 
displaced. The beating aggregates of CMCs were counted daily (Figure 10A and B).
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Figure 10: Serum concentration during CVPC in vitro differentiation influences quantity, maximal number and 
longevity of active CMCs: 
A: Quantity of beating areas of CMCs from day 14 to day 26 when fed with medium containing 15%, 10% and 5% 
FBS. 
B: Comparison of the number of beating CMCs in CVPCs at the maximum of activity on day 17 when fed with 
medium containing 15%, 10% and 5% FBS. 
 
The medium containing the highest concentration of 15% v/v fetal bovine serum was 
the most favorable for efficient differentiation of CVPCs to CMCs. Furthermore, a 
higher concentration of FBS caused a higher longevity of beating CMCs. Fetal bovine 
serum does not have a defined composition, and in this setup it was not determined 
which factors in the serum are influencing cardiomyogenesis.  
4.4 Effects of leukemia inhibitory factor on CVPC differentiation 
LIF is usually used to maintain mESCs or CVPCs undifferentiated. However, Bader et al 
(2001) showed that in EBs, LIF promotes proliferation of cardiomyocytes in a 
developmental stage-dependent manner (see introduction page 14). Further 
experiments in the Weitzer laboratory demonstrated a cardiomyogenesis-promoting 
effect of M-LIF on CVPCs as well (Wiedner 2008). LIF expressed in SF9 insect cells which 
are ovarial cells of Spodoptera frugiperda, showed a higher cardiomyogenesis-
promoting impact on mESCs than recombinant LIF produced in bacteria which lacks 
eukaryotic modification of proteins. Therefore LIF was expressed in SF9 cells and 
tested on CVPCs. 
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4.4.1 Expression of M-LIF and D-LIF in SF9 insect cells 
The LIF-gene codes for three different isoforms of LIF: Truncated (T-LIF), matrix 
associated (M-LIF) and diffusible LIF (D-LIF), which are generated by alternative 
splicing. M and D-LIF have almost the same size and sequence but differ in their N-
terminal amino acid-sequence, a putative leader sequence.  
D-LIF:  MKVLAAGIVPLLLL... 
M-LIF:       MRCRIVPLLLL... 
Although M-LIF and D- LIF are both secreted, they may have different effects as was 
shown by former studies (Conquet et al. 1992; Pasteiner 2006). Truncated LIF remains 
inside the cell.  
The SF9- Baculovirus system was chosen because in contrast to bacterial expression 
systems insect cells also generate posttranslational modifications in expressed proteins 
such as phosphorylations, myristylations, palmitylations, and glycosylations. LIF is 
known to be heavily glycosylated, thus glycosylation will have an effect on activity and 
function of LIF. SF9 cells were infected with viruses containing M-LIF and D-LIF 
expression vectors. SF9 cells were infected with baculoviruses containing M-LIF and D-
LIF expression vectors constructed by Waltraud Pasteiner (Pasteiner 2006). A viral 
plaque assay done by Marc Wiedner showed that both viruses exhibit a titer of 2.2x10
5
 
plaque forming units (PFU) per ml. A multiplicity of infection (MOI) of 0.01PFU/cell was 
used for both infections. 4 days after infection cells were harvested and stored at -
80°C. Infected cells are bigger in size and appear bloated and granular (Figure 11).  
 
 
Figure 11: SF9-cells before and after baculovirus infection. Bar=10 µm 
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4.4.2 Purification of M-LIF and D-LIF 
SF9 cells were lysed and the M-LIF and D-LIF proteins were purified using Ni
2+
-NTA 
agarose beads. Expressed M-LIF and D-LIF proteins are histidine-tagged and contain a 
stretch of 6 histidines at the C-terminus which binds to Ni
2+
. The LIF proteins were 
eluted with imidazole and fraction 1-4 were collected; the first two were eluted with 
50 mM imidazol and the last two with 250 mM imidazol, respectively. The collected 
fractions were analysed on a 12% SDS-polyacrylamide gel (Figure 12). M-LIF and D-LIF 
are 30-40 kDa in size, depending on the degree of glycosylation. Unglycosylated D-LIF 
and M-LIF have a calculated mass of 22.29 kDa and 22.16 kDa, respectively. 
 
Figure 12: SDS-PAGE of D-LIF, M-LIF and control (uninfected SF9-cells) Ni
2+
-NTA agarose fractions.  
 
On the coomassie-stained SDS-PAGE no defined band could be assigned to LIF, because 
the control showed the same pattern as M-LIF and D-LIF. To verify the presence of LIF 
in the elution a western blot with αLIF-antibody was performed (Figure 13). 
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Figure 13: Western blot of M-LIF and D-LIF SDS-PAGE (α-LIF 1:500): The differentially glycosylated forms of LIF 
range from 40 kDa to 22 kDa a truncated form of LIF appears at 17 kDa.  
On the western blot, fraction 3 and 4 where 250 mM imidazole was used for the 
elution, contained the highest amount of LIFs. The blot showed the presence of M-LIF 
and D-LIF with differing levels of glycosylation between 22 and 40 kDa in size. D-LIF 
fractions contained the highest concentration of LIF. Furthermore, a truncated form of 
LIF was present at 17kDa. Before usage of M-LIF and D-LIF for further experiments in 
cell culture the LIF containing fractions were dialysed in order to get rid of heavy metal 
ions and imidazol.  
 
4.4.3 LIF promotes cardiomyogenesis in CVPCs 
To investigate the effect of LIF isoforms on cardiomyogenesis during CVPCs 
differentiation CVPCs were treated with 100 ng/ml M-LIF, D-LIF and recombinant LIF 
(R-LIF) and as a control with the extraction of uninfected SF9 cells (SF9), respectively 
and compared to untreated CVPCs (CT). Clones B5 (Figure 14A and B) and H3 (Figure 
15A and B) were seeded onto gelatin coated cell culture dishes and treated with LIFs or 
controls for 4 days. Afterwards, the medium was exchanged and differentiating CVPCs 
were observed by phase contrast microscopy. Beating areas of CMCs were counted 
daily.  
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Figure 14: Beating areas of cardiomyocytes after LIF-promoted differentiation of CVPC clone H3. 1x10
5
 CVPCs 
clone H3 were seeded onto a gelatin coated 6-well plate and treated with 100 ng/ml M-LIF, D-LIF, R-LIF or the 
control extraction (SF9) or left untreated (CT) for 4 days.  
A: Comparison of number of beating CMCs for each day of activity. 
B: Comparison of the maximum of beating CMCs which occurred at different days, respectively. 
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Figure 15: Beating areas of cardiomyocytes after LIF-promoted differentiation of CVPC clone B5. 1x10
5
 CVPCs 
clone B5 were seeded onto a gelatin coated 6-well plate and treated with 100 ng/ml M-LIF, D-LIF, R-LIF or the 
control extraction (SF9) or left untreated (CT) for 4 days.  
A: Comparison of number of beating CMCs for each day of activity.  
B: Comparison of the maximum of beating CMCs at day 21. 
 
In H3 M-LIF and D-LIF but not R-LIF showed a cardiomyogenesis promoting effect when 
compared to SF9 and CT. In B5 all LIFs promoted cardiogenic differentiation.  
 
4.5 Expression of stem cell and cardiomyogenic markers in CVPCs and 
cardiomyocytes 
4.5.1 Stem cell markers Oct3/4, Nanog, Sox2 and mTERT are expressed in CVPCs 
2 CVPC clones (G3, H3) were maintained undifferentiated on SNL76/7 feeder cells and 
the mRNA of clones G3 and H3 was isolated and analyzed by a semi-quantitative RT-
PCR (Figure 16A-C). The markers Oct3/4 and Nanog are both transcribed in CVPCs. 
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Oct3/4 and Nanog are critical stem cell transcription factors which are also expressed 
in ESC and indicate pluripotency. Telomerase, the enzyme which maintains the 
telomeres of linear chromosomes in eukaryotes, is only transcribed in stem cells and 
especially in ESC at high levels. In somatic stem cells mTERT is found at lower levels. In 
comparison to ESC CVPC clone H3 expresses low levels of mTERT. Sox2 (sex 
determining region Y)-box 2 which is essential for mESCs self renewal is expressed in 
CVPC clone H3 as well. In summary the main transcription factors Oct3/4, Sox2 and 
Nanog which build the transcriptional network of self renewal in mESCs are present in 
CVPCs, too. 
 
Figure 16: RT-PCR of mRNAs transcribed in CVPCs:  
A: Oct3/4 and Nanog mRNAs are transcribed in CVPC clone G3 and H3. As a control PCR genomic mouse DNA (C3H) 
was used. 
B: mTERT (murine telomerase reverse transcriptase) is expressed in clone H3. As a control mESCs mRNA (AB2.2) and 
genomic DNA (C3H) including introns was used. CVPC clone H3 transcribes mTERT at lower levels than mESCs AB2.2. 
C: Sox2 is expressed in clone H3. As a control PCR genomic mouse DNA (C3H) was used. 
 
4.5.2 Transcription of cardiac transcription factors is up-regulated during CVPC 
differentiation  
During differentiation CVPCs should upregulate cardiogenic transcription factors. CVPC 
differentiation was induced by cultivation on gelatin-coated culture plates and 
treatment with 100 ng/ml M-LIF for 4 days. mRNA of beating CMCs was isolated 16 
days after M-LIF treatment. Semiquantitative RT-PCR showed that cardiac transcription 
factors Nkx2.5, GATA4 and muscle cell markers Tropomyosin and MEF2C and Desmin 
were upregulated in CMCs (Figure 17). Isl1 is a LIM-homeodomain transcription factor 
which is expressed in cardiac progenitor cells of the second heart field during 
embryogenesis. Isl1 was found to be expressed in CVPC and at higher levels in CMCs.  
 A  B  C 
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Figure 17: Cardiac transcription factors are up-regulated during CVPC differentiation:  
Comparison of mRNA expression in clone B5, G3 and H3 undifferentiated CVPCs and differentiated CVPCs day 16.  
 
4.5.3 Cardiac transcription factor Nkx2.5 expression is up-regulated within 48 hours 
in differentiating CVPCs 
To determine the onset of expression of the cardiac transcription factor Nkx2.5 on 
translational level, western blots of differentiating CVPCs were done. CVPC clone H3 
was seeded on gelatin-coated culture plates at a concentration of 1x10
5
cells per 4 ml 
in 6-well plates. Differentiating cells were harvested every 24 hours for blotting. 
Sample protein concentrations were measured with a NanoDrop 1000 UV/VIS 
fluorospectrometer and diluted to equal concentrations. For western blotting primary 
αNkx2.5 antibodies and secondary alkaline phosphatase conjugated antibodies were 
used (Figure 18). After 48 hours of differentiation Nkx2.5 proteins were detected for 
the first time. Between day 2 and 6 Nkx2.5 concentration was rising and on day 7 a 
slight reduction of Nkx2.5 protein was seen. Nkx2.5 mRNA is not present in 
undifferentiated CVPCs but Nkx2.5 translation is activated within 48 hours of 
differentiation. The quick up-regulation of the heart specific transcription factor 
Nkx2.5 demonstrates the immanent cardiomyogenic differentiation potential in CVPCs. 
 
Figure 18: Nkx2.Westernblot day 1 to 7 (1-7). Nkx2.5 expression begins at day 2 and is up-regulated during day 2 to 
6 and slightly down-regulated at day 7. 
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4.6 Effects of SPARC and BMP2 on CVPC differentiation 
SPARC is an essential protein which promotes cardiac development in embryoid bodies 
(Stary et al. 2005). Furthermore, Martina Stary showed that in EBs BMP2 promotes 
cardiogenesis and that SPARC and BMP2 synergistically induce expression of Nkx2.5. 
Therefore, SPARC and BMP2 may promote cardiogenesis in CVPCs as well.  
 
4.6.1 SPARC is expressed in CVPCs 
Again, CVPC differentiation was induced by cultivation on gelatin-coated culture plates 
and treatment with 100 ng/ml M-LIF for 4 days. The mRNA of differentiated CVPCs 
containing beating CMCs was isolated 16 days after M-LIF treatment. To determine 
whether SPARC and BMP2 are transcribed in undifferentiated CVPCs and differentiated 
CVPCs or not, a semi-quantitative RT-PCR was done. RT-PCR showed that SPARC mRNA 
is expressed in both, CPVCs day 0 and day 16. BMP2 is slightly upregulated in 
differentiated CVPCs (Figure 19). 
 
 
Figure 19: RT-PCR of SPARC and BMP2 in 3 CVPC clones at day 0 and day 16 of differentiation. SPARC is expressed 
at day 0 and day 16 and BMP2 expression becomes apparent at low levels in differentiated CMCs. 
 
To detect where the SPARC protein is present in CVPCs, differentiating CVPC 
aggregates with beating CMCs were ethanol fixed at day 16 and immunostained with 
SPARC antibodies (Figure 20). As secondary antibodies Texas red anti-rabbit were used 
and nuclei were stained with DAPI. SPARC filled vesicles were found throughout the 
cytoplasma of CVPCs but not in the nucleus (blue).  
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Figure 20: Vesicles-like structures in differentiated CVPCs contain SPARC: SPARC labeled with Texas red secondary 
antibodies is present in the cytoplasma. Nucleus is stained blue with DAPI. 
 
4.6.2 SPARC promotes cardiomyogenesis in CVPCs in vitro 
If SPARC induces cardiomyogenesis in CVPCs like in EBs, treatment with recombinant 
SPARC should promote cardiomyogenesis in CVPCs. In a newly developed 
differentiation procedure 6-well cell culture plates were gelatin-coated and 3 plastic 
rings per well, cut out of Gilson pipette tips, were glued to the plates with sterile 
Vaseline. The rings were confined water-proof wells with a volume of 500 µl in which 
cells can be treated separately from the rest of the well. 8000 undifferentiated CVPCs 
clone H3 in 300 µl medium (M15Hy) were seeded into the rings and treated with 2 
µg/ml SPARC for 4 days or left untreated as a control. 8000 CVPCs in a ring equates to 
seeding 110.000 CVPCs into a 6-well culture plate. After 4 days the rings were 
displaced to use the whole volume of the well to prevent starvation by lack of medium. 
Afterwards, the medium was exchanged every second day. Beating CMCs were 
observed and counted daily. The onset of beating CMCs was at day 16 at the same 
time in SPARC treated cells and untreated cells, but the quantity of beating CMC was 2-
fold higher in SPARC treated cells at day 20 (Figure 21A) and 3-fold higher on average 
between day 16 and 32 (Figure 21B). 
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Figure 21:  SPARC promotes cardiomyogenesis in CVPCs:  
A: Comparison of quantity of beating areas of CMCs in untreated (CT) and SPARC treated CVPCs (SPARC) from day 
16 to day 31. 
B: Average of beating areas of CMCs in untreated (CT) and SPARC treated cells (SPARC) between day 16 and day 32. 
 
In a second experiment 3x10
5 
CVPCs clone B5 and G3 were seeded on gelatin-coated 6-
well plates and treated with M-LIF (100 ng/ml) for 4 days. Afterwards 1x10
5 
of the cells 
were treated with BMP2 (100 ng/ml), SPARC (2µg/ml) and SPARC plus BMP2 for 11 
days (Figure 22). SPARC treated cells beat 2 days prior to cells treated with M-LIF only. 
BMP2 (bone morphogenetic protein 2) a factor which promotes cardiomyogenesis in 
embryoid bodies did not induce cardiomyogenesis in CVPCs in monolayers and CVPCs 
remained morphologically unchanged. BMP2 inhibited SPARC induction of 
cardiomyogenesis when cells were treated with both SPARC and BMP2. 
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Figure 22: Influence of SPARC
A: Comparison of quantity of beating areas of CMCs in 
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Figure 23: Temporary SPARC inhibition hampers cardiomyogenesis: 
A: Comparison of quantity of beating areas of CMCs in untreated (Control), SPARC treated (SPARC) and SPARC 
antibodies treated CVPCs clone H3 (Anti SPARC) from day 14 to day 26. 
B: Average of beating areas of CMCs in untreated (Control), SPARC treated cells (SPARC) and SPARC antibodies 
treated CVPCs clone H3 (Anti SPARC) between day 16 and day 24. 
 
4.6.3 SPARC induces cardiac transcription factor expression indirectly  
During differentiation of CVPCs, cardiac transcription factors have to be expressed for 
cardiomyogenesis. To see if cardiac marker genes transcription is induced by SPARC, 
CVPCs were treated with SPARC (2µg/ml) and mRNA was isolated 0, 2, 4, 6 and 12 
hours after treatment for a semi-quantitative RT-PCR. As a control, CVPCs treated for 
12 hours with BMP2 inhibiting cardiomyogenesis was used (Figure 24).  
Mesp1 a helix-loop-helix protein which is expressed in all cardiovascular precursor 
cells, was down-regulated within 2 hours in SPARC and BMP2 treated CVPCs. Desmin a 
muscle specific type-III-intermediary filament was not upregulated within 12 hours. 
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SPARC was strongly expressed in all cells regardless of treatment. GATA4 was stably 
expressed in SPARC treated cells but down-regulated in BMP2 treated cells. The early 
cardiac marker Nkx2.5 was not expressed in SPARC or BMP2 treated cells within the 
first 12hours. No short term up-regulation of cardiac marker genes was observed.  
 
 
Figure 24: Cardiac marker gene expression in CVPCs during SPARC induced differentiation: mRNA was isolated 0h, 
2h, 4h, 6h, and 12h after seeding. BMP2 treated cells were harvested after 12h. Myocardial transcription factor 
GATA4 was down-regulated in BMP2 treated cells.  
 
Because Nkx2.5 expression is mandatory for cardiomyogenesis and Nkx2.5 is present in 
CMCs at day 16, but not within the first 12 hours of differentiation, (Figure 25) an 
experiment with a larger time scale was designed. 3x10
5
 CVPCs were seeded and 
treated with M-LIF or left untreated for 4 days. At day 4, 60.000 cells were re-seeded in 
gelatin-coated 6-well culture plates and treated with SPARC (0.5 µg/ml) and BMP2 
(100 ng/ml). mRNA was isolated after 24 hours (day 1), 48 hours (day 2), and 96 hours 
(day 3) and analyzed by semi quantitative RT-PCR (Figure 13). M-LIF and SPARC 
induced strong Nkx2.5 expression at day 2. In untreated cells and BMP2 treated strong 
Nkx2.5 expression was observed 24 hours later at day 3.  
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Figure 25: Nkx2.5 expression in differentiating CVPCs: Nkx2.5 is upregulated 24 hours earlier in SPARC or M-LIF 
treated CVPCs in comparison to BMP2 and untreated CVPCs.  
The 2 SPARC differentiation experiments indicate that Nkx2.5 is indirectly activated by 
SPARC after 24 hours. Adding SPARC in excess accelerates Nkx2.5 transcription and 
promotes cardiomyogenesis in CVPCs. 
 
4.7 Activating the Wnt pathway by GSK3 inhibition keeps CVPCs 
undifferentiated  
How SPARC promotes cardiomyogenesis is unclear. SPARC physically interacts with 
ILK1 (Barker et al. 2005). ILK1 is known to inhibit GSK3 (Dedhar 2000), thereby 
activating the canonical Wnt pathway. Recently, there was evidence that Wnt is an 
essential regulator of cardiac progenitor cell differentiation (Cohen et al. 2008). 
Especially the canonical Wnt pathway promotes differentiation of mesodermal 
progenitors into CMCs in EBs (Kwon et al. 2007). Furthermore, Wnt signaling promotes 
Nkx2.5 expression and early cardiomyogenesis in mouse embryonic carcinoma stem 
cells (Liu et al. 2009). All these recent experiments indicate that SPARC may indirectly 
activate or contribute to activation of Nkx2.5 via ILK/GSK3-linked activation of the 
Wnt-pathway. To check if the Wnt-pathway induces cardiomyogenesis in CVPCs, the 
Wnt-pathway was activated by GSK3 inhibition. Therefore, CVPCs were treated with 
CHIR99021, which is a potent chemical specifically inhibiting GSK3. 3x10
5
 CVPCs clone 
H3 were seeded on 6-well plates and treated with CHIR99021 (1.4 µg/ml) for 4 days. A 
higher quantity of CVPCs was seeded because CVPCs were fed with medium containing 
15% horse serum which is of lower quality than bovine serum and the optimal CVPC 
concentration for differentiation is higher than in FBS. Several differentiation 
experiments showed that seeding 3x10
5
 CVPCs is the best density for autonomous 
cardiomyogenesis of CVPCs in horse serum (data not shown). Beating CMCs were 
observed from day 14 until day 26 in untreated but not in CHIR99021-treated CVPCs 
(Figure 26). CVPCs treated with CHIR99021 remained undifferentiated with a small and 
round morphology.  
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Figure 26: CHIR99021 inhibits differentiation in CVPCs. Untreated CVPCs clone H3 (H3) efficiently differentiated to 
CMCs whereas CHIR99021 treated CVPCs (CHIR99021) remained undifferentiated. 
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5 Discussion 
5.1 Cultivation of CVPCs 
The CVPCs were isolated from the heart tissue of neonatal mice. Neonatal hearts 
express LIF (Robertson et al. 1993) and LIF together with other factors maintains 
mESCs undifferentiated. This led to the idea that CVPCs can be cultivated on LIF 
expressing SNL 76/7 fibroblast feeder cells. It turned out that when cultivated on 
feeder cells CVPCs remain undifferentiated and proliferate for at least 60 passages 
without losing their differentiation potential (data not shown). DMEM and fetal bovine 
serum were sufficient to feed CVPCs and common mammalian cell culture incubators 
and conditions were used. CVPCs have to be cultivated sub-confluent and splitting is 
necessary every 3 days. Careful cryo-conservation in liquid nitrogen does not change 
the characteristics of CVPCs. The morphology of CVPCs differs in size and shape when 
compared to that of mESCs. CVPCs appear smaller in size and they do not adhere to 
each other when cultivated on feeder cells.  
5.2 Spontaneous in vitro differentiation potential of CVPCs 
The first in vitro differentiation experiment with cardiac bodies led to the name CVPCs. 
In mESCs pluripotency can be demonstrated in vitro with embryoid body experiments 
where mESCs spontaneously differentiate into every cell type of the early embryo 
except trophoectoderm. In cardiac bodies however, CVPCs spontaneously 
differentiated to a restricted number of cell types. Cells of the cardiovascular system, 
endodermal cells, contracting smooth muscle cells (SMCs), and beating heart cells 
(CMCs), were observed and endothelial-like cells formed bubbles on the periphery of 
CBs. No other cell types which develop in embryoid bodies like neuronal cells and 
skeletal muscle cells were seen. Thus, the cardiac body experiment shows 
morphologically the limited differentiation potential of CVPCs in vitro. Interestingly, in 
CBs of different clones CMCs and SMCs developed at different rates. This may be due 
to differences between the clones or simply to differences in experimental handling. 
The fact that the more CMCs the less SMCs were active and vice versa, may be a result 
of changing conditions during the experiment. As CVPCs keep proliferating during 
differentiation, the cell density is rising, more cytokines and fewer nutrients are 
present and the number of cells undergoing apoptosis is rising. Furthermore. the 
composition of different cell types is changing. 
The detection of cTnT by immunofluorescence microscopy verified the presence of 
CMCs in CBs. cTnT was present within myofilaments in the typical striated pattern. 
Clusters of cTnT also correspond to the beating interwoven networks and clusters of 
CMCs which were observed by immunofluorescence microscopy in CBs. Smooth 
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muscle cell actin, a SMC marker, was also detected by immunofluorescence 
microscopy recently (Hoebaus, 2009). Hence, CVPCs differentiate to CMCs and SMCs 
which are part of the cardiovascular system. The existence of other cell types in CBs, 
like the putative endothelial cells, has to be confirmed by further immunofluorescence 
experiments. 
Monolayer differentiation experiments with CVPCs on gelatin-coated culture plates 
also resulted in efficient differentiation to beating CMCs. In contrast to mESCs, CVPCs 
differentiated to CMCs when seeded sub-confluent. These experiments showed that 
CVPCs differentiate autonomously without any treatment to beating CMCs within 12 
days. However, no SMCs were observed. Efficient and autonomous differentiation to 
CMCs was shown for all 11 CVPC clones (Hoebaus, 2009). Depending on the quantity of 
seeded cells different amounts of beating cardiomyocytes were observed. 
Furthermore, the more beating CMCs were present the earlier was the onset of CMC 
activity. Seeding 1x10
5
 cells of clone H3 resulted in the highest number of CMCs. 
Seeding more cells led to less CMC development and seeding fewer cells did not result 
in any beating CMCs. This indicates that there is an ideal cell density needed for 
efficient cardiomyogenic differentiation. Reasons for this may be factors like cell-cell 
interactions and concentration of cytokines or nutrients in the medium. One difference 
between monolayer experiments and CBs was, when the CVPCs were seeded in 
monolayers at a low density, in contrast to CBs cell-cell interactions were not existent 
but formed when the cells proliferated and became confluent. If cells are seeded 
confluent or nearly confluent no CMCs develop in monolayer experiments. Because in 
both CBs and monolayer experiments CMCs arise efficiently, it can be concluded that 
cell-cell interaction has a minor impact on cardiomyogenic differentiation of CVPCs. 
Factors secreted by differentiating CVPCs or factors present in the medium might be 
the key regulators of the cardiomyogenic differentiation process. 
5.3 Influence of fetal bovine serum on differentiation 
Fetal bovine serum is the part of blood plasma which remains after the coagulation 
and centrifugation of fetal bovine blood. It is a growth supplement used for cell culture 
and it is produced by many different manufacturers. The main component is the 
protein bovine serum albumin (BSA) and it contains a lot of other proteins and 
cytokines like BMPs which influence the differentiation of cells. The composition is not 
defined and differs between origins and manufacturers. To investigate which impact 
the concentration of our FBS from the company Hyclone has on the differentiation 
efficiency of CVPCs, CVPCs were differentiated in media with different FBS 
concentrations. The experiment showed that higher concentrations of FBS promoted 
cardiomyogenesis of CVPCs and enhanced the longevity of the resulting CMCs. This 
effect can be a direct consequence of factors in the FBS inducing cardiomyogenesis or 
a consequence of FBS-feeding by promoting growth, proliferation and survival of 
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CVPCs and thereby stimulating cardiomyogenesis indirectly. Because the FBS 
composition is not defined and changes even from batch to batch of one company, it is 
difficult to determine which factors in the FBS are responsible for the 
cardiomyogenesis promoting effect. In further experiments by using differentiation 
media containing a defined composition of nutrients and growth factors, the influence 
of the medium on cardiomyogenesis and differentiation of CVPCs could be 
determined. 
5.4 Influence of LIF on differentiation 
LIF promotes cardiomyogenesis in EBs (Bader et al. 2001) and the addition of LIF 
isoforms to the medium of monolayers of CVPCs is a promising way to promote 
cardiomyogenesis in CVPCs. Although slight fluctuations in the outcome of CMC 
differentiation were present, as expected both M-LIF and D-LIF promoted 
cardiomyogenesis in experiments with clone H3 and clone B5. R-LIF the recombinant 
LIF-isoform isolated from bacteria and lacking posttranslational modifications did not 
have a clear effect.  
 
Like in mESCs, LIF in CVPCs is an ambiguous factor inhibiting differentiation when 
CVPCs are cultivated on feeder cells and inducing differentiation when high 
concentrations of LIF are added for 4 days to sub-confluent monolayers of CVPCs 
growing on gelatin-coated culture plates. An explanation to this paradox is that excess 
LIF preferentially activates the ERK1 pathway whereas less LIF keeps CVPCs and ESC 
undifferentiated by activating the JAK/STAT-pathway. The MAPK-pathway and 
JAK/STAT-pathway are antagonizing each other (Niwa et al. 2009). Furthermore, 
undifferentiated CVPCs are almost confluent when grown on feeder cells in contrast to 
CVPCs seeded for differentiation thereby changing the concentration of LIF per CVPC. 
Another explanation is that LIF only promotes self renewal and proliferation of CVPCs 
and thereby increases cardiomyogenesis and that differentiation starts after the 4 day 
treatment with LIF. In further experiments Hoebaus (Hoebaus, 2009) showed that in 
CVPCs cultivation SNL76/7 feeder cells can be substituted by M-LIF without any loss of 
self-renewal capability.  
 
5.5 CVPCs mRNA expression profile: Stem cell markers and cardiac 
marker gene expression  
Stem cells have to express stemness markers to maintain their self-renewal capability. 
Recently a study showed, that 3 main transcription factors exist, which regulate self-
renewal (Ying et al. 2008). Oct3/4, Nanog and Sox2 are the key stemness markers in 
mESCs. Although CVPCs are not embryonic stem cells they showed some self-renewal 
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capability by proliferating for at least 60 passages without loss of self-renewal and 
differentiation potential. Therefore, we were interested in the expression of Oct3/4, 
Nanog and Sox2 in CVPCs. 
The Semi-quantitative RT-PCR showed that CVPCs transcribe all 3 essential 
transcription factors Oct3/4, Nanog and Sox2 which are required for stem cell self-
renewal. This result confirms that CVPCs probably have stem cell character. Besides 
CVPCs self-renewal might be regulated similar to mESCs. 
 
Another stemness marker is the enzyme telomerase. Telomerase consists of an RNA 
component (TER) that carries a short template complementary to telomere DNA, and a 
reverse transcriptase (TERT) that copies the RNA template to the 3'-end of linear DNA. 
The telomerase enzyme elongates telomeres of linear chromosomes in eukaryotes 
which otherwise would shorten during each cell division until cells become senescent 
or apoptotic. By inhibiting senescence telomerase thereby allows unlimited cell 
divisions. TERT is highly expressed in cells that divide extensively like some immune 
cells of eukaryotes, germ cells, stem cells and in cancer cells. Somatic cells express 
TERT at very low levels. RT-PCR showed that CVPCs do express mTERT. But in 
comparison to mESCs AB2.2 the expression level is low which is typical for adult stem 
cells and progenitor cells (Harrington 2004). In further experiments the enzymatic 
activity of telomerase in CVPCs should be determined and compared to that of mESCs. 
To determine the enzymatic activity a telomeric repeat amplification protocol (TRAP) 
assay has to be done. In TRAP cells are lysed and the telomerase is extracted. 
Afterwards a DNA substrate similar to telomeres is mixed with the telomerase and the 
quantity of elongated fragment is determined by PCR (Kim et al. 1994). 
 
Besides expression of self-renewal transcription factors in CVPCs, cardiac-specific gene 
expression was of interest. Furthermore, the up-regulation of these genes during 
differentiation of CVPCs to CMCs was investigated. A comparative semiquantitative RT-
PCR of undifferentiated CVPCs and CVPCs which had differentiated for 16 days was 
done. The RT-PCR showed that transcription factors Nkx2.5 and GATA4 which are 
expressed in differentiating CMCs are not present in undifferentiated CVPCs. But after 
16 days of differentiation strong Nkx2.5 and GATA4 expression was detected. This 
expression of CMC transcription factors matches with the observation that CVPCs 
differentiate to beating CMCs within 16 days. MEF2C is a transcription factor which is 
necessary for correct development of heart and vasculature in embryos (Bi et al. 1999). 
MEF2C is present in CVPCs at day 0 and was upregulated during CVPCs differentiation 
in all clones, also in G3 which was confirmed in further experiments (Hoebaus, 2009). 
The myocyte specific proteins Tropomyosin and Desmin were not present in CVPCs at 
day 0 but up-regulated in CVPCs day 16. Isl1 is a LIM-homeodomain transcription 
factor which is expressed in cardiac progenitor cells of the second heart field during 
embryogenesis. Isl1 was found to be expressed in CVPCs at day 0 and at higher levels 
in CVPCs day 16. The RT-PCR showed that early premyocardial transcription factors like 
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MEF2C and Isl1 are expressed in CVPCs and are upregulated during differentiation. 
Muscle specific proteins like Tropomyosin and Desmin and early precardiac 
transcription factors like Nkx2.5 and GATA4 were present in differentiated CVPCs at 
day 16. 
In summary, CVPCs express transcription factors OCT3/4, Sox2 and Nanog which 
maintain self-renewal in mESCs. They express telomerase at low levels in comparison 
to mESCs but its enzymatic activity needs to be determined. Early premyocardial 
transcription factors are expressed and myocardial specific transcription factors are 
upregulated during autonomously differentiation. Myocyte specific proteins are 
expressed in differentiated CVPCs. CVPCs mRNA expression shows stem cell and 
cardial characteristics. 
 
5.6 Translation of Nkx2.5 during CVPCs 
The Nkx2.5 homeodomain protein is a marker of early precardiac cells and essential for 
heart formation in embryos (Durocher et al. 1997). Nkx2.5 is observed in heart tissue 
during the time of cardiac differentiation (Harvey et al. 2002). While RT-PCR showed 
that Nkx2.5 is upregulated in CVPCs between day 0 and day 16 of differentiation we 
were interested in the time at which Nkx2.5 is upregulated on a translational level. 
Therefore, monolayer differentiation experiments with CVPCs clone H3 were done and 
each 24 hours a well with CVPCs was harvested. The protein concentrations were 
normalized and prepared for SDS-PAGE. The SDS-PAGE was then western blotted with 
Nkx2.5 antibodies. Western blotting revealed that Nkx2.5 proteins are detectable for 
the first time after 48 hours of differentiation. The Nkx2.5 protein concentration 
continued to rise until day 6. At day 7 a reduction of Nkx2.5 was observed. Thus, the 
cardiac transcription factor Nkx2.5 was continuously up-regulated during 
differentiation of CVPCs on a protein level after 24 hours and rose between days 2 and 
6. A decrease of Nkx2.5 began at day 7. For further information on Nkx2.5 translation 
levels further samples of differentiating CVPCs have to be taken and compared.  
5.7 Influence of SPARC and BMP2 on differentiation 
SPARC and BMP2 are versatile proteins which have different effects on different cell 
types. It was shown that SPARC is expressed during muscle development and in 
regeneration of muscle tissue and it is present in myoblasts, myotubes and muscle 
fibers. During embryogenesis SPARC is expressed in the heart primordial. It was shown 
that SPARC promotes cardiomyogenesis in EBS (Stary et al. 2005). 
 
Without BMP2, early embryos have an abnormal cardiac development and fail in 
amnion and chorion formation (Zhang and Bradley 1996). BMP2 is essential for early 
heart development and induces expression of cardiac marker genes like Nkx2.5 and 
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GATA4 (Schlange et al. 2000). Stary (Stary et al. 2005) demonstrated a synergistically 
cardiomyogenesis promoting effect of SPARC and BMP2 in EBs. All this evidence led to 
the hypothesis that SPARC and BMP2 have a cardiomyogenesis promoting effect on 
CVPCs. 
 
First of all, the mRNA expression of SPARC and BMP2 in CVPCs was determined. 
Semiquantitative RT-PCR showed that SPARC-mRNA is transcribed in CVPCs and in 
differentiating CVPCs at day 16. BMP2 was not expressed in undifferentiated CVPCs 
but at low levels in day 16 CVPCs. Nevertheless BMP2 could influence the 
differentiation of CVPCs because fetal bovine serum (FBS) contains several BMPs and a 
study in 2006 showed that BMPs can be purified from FBS (Kodaira et al. 2006). Thus, 
BMPs are present in the medium during CVPC differentiation. However, if BMPs in 
fetal bovine serum are specifically inhibited, myogenic differentiation is stimulated 
(Kodaira et al. 2006). But the monolayer CVPC differentiation experiments with 
different concentrations of FBS showed that a high FBS concentration and thus a high 
BMP concentration are favorable for cardiomyogenesis.  
To affirm the SPARC expression on a translational level an immunofluorescence 
microscopy of differentiated CVPCs at day 16 was done. Immunostaining showed that 
each CVPC at day 16 is full of structures resembling vesicles containing SPARC. If the 
structures are vesicles, SPARC is probably secreted as an autocrine differentiation 
factor. Interestingly, all differentiated CVPCs contained SPARC regardless of cell type.  
 
Secondly, the effect of adding an excess of SPARC to differentiating CVPCs was 
investigated. CVPCs were treated with 2 µg/ml for the first 4 days of differentiation 
and compared to untreated CVPCs. The addition of SPARC strongly promoted 
cardiomyogenesis. Notably, the onset of beating CMCs was at the same at day 16 but 
the number of beating CMCs was much higher in SPARC treated cells. On average, a 3-
fold higher number of CMCs was counted in CVPCs treated with SPARC. The conclusion 
is that SPARC promotes cardiomyogenesis in vitro in monolayer differentiation. The 
same effect was demonstrated in embryoid bodies and during embryogenesis. 
Differentiation of CVPCs to CMCs is not accelerated by SPARC but more efficient. 
 
Because M-LIF and SPARC had both shown a cardiomyogenesis promoting effect, a 
combination of them could improve cardiomyogenesis. Also because high FBS 
concentrations promoted cardiomyogenesis and FBS contains BMPs, the effect of 
excess BMP2 on cardiomyogenesis was investigated. CVPCs were treated with M-LIF 
for 4 days and afterwards SPARC, BMP2 and a combination of SPARC and BMP2 was 
added for 11 days. Again, M-LIF and SPARC treated CVPCs efficiently differentiated to 
CMCs. CVPCs treated with M-LIF only, also differentiated to CMCs but at a lower 
quantity. In comparison, M-LIF/SPARC treated CVPCs had a 2.5-fold higher average of 
active CMCs between day 12 and 19 than M-LIF treated CVPCs. CVPCs that were 
treated with M-LIF/BMP2 or M-LIF/BMP2 and SPARC did not differentiate to CVPCs. 
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Interestingly, BMP2 overruled the cardiomyogenesis promoting effect of both M-LIF 
or/and SPARC. In summary, SPARC enhances the cardiomyogenesis promoting effect of 
M-LIF. Surprisingly, BMP2 inhibited cardiomyogenesis at least at this concentration and 
in this experimental setup. However, further experiments showed that BMP2 
promotes cardiomyogenesis when added for a shorter time period (Hoebaus, 2009). 
Because excess SPARC promotes cardiomyogenesis and SPARC is strongly expressed in 
CVPCs, the hypothesis was tested that an inhibition of endogenous SPARC with 
neutralizing antibodies inhibits cardiomyogenesis. In a new differentiation experiment 
CVPCs were treated with SPARC and SPARC antibodies and compared to CVPCs which 
were left untreated. As expected, SPARC promoted and SPARC neutralizing antibodies 
hampered cardiomyogenesis in CVPCs in comparison to untreated CVPCs. Treatment 
with SPARC antibodies resulted in less beating CMCs and CMCs started to beat 3 days 
later. Thus, endogenous SPARC is essential for the duration and the efficiency of 
cardiomyogenic differentiation of CVPCs. 
 
5.8 SPARC signaling in CVPCs 
To investigate if SPARC directly induces expression of mesodermal, precardiac and 
myocyte marker genes in CVPCs, CVPCs were treated with SPARC and the mRNA was 
isolated 0, 2, 4, 6 and 12 hours after treatment. As a control, CVPCs were treated with 
BMP2 to prevent differentiation. The expression of precardiac marker genes Nkx2.5 
and GATA4, the cardiac myocyte gene desmin and the cardiovascular precursor marker 
gene Mesp1 were studied. Former RT-PCR experiments showed that Nkx2.5, GATA4 
and Desmin are expressed in differentiated CVPCs at day 16. But during the first 12 
hours of SPARC treatment Nkx2.5 was not expressed at detectable levels in SPARC or 
BMP2 treated CVPCs. GATA4 was expressed at constant levels and in BMP2 treated 
CVPCs GATA4 was down-regulated. The cardiovascular precursor marker gene Mesp1 
was down-regulated after SPARC and BMP2 treatment. The myocyte specific 
intermediary filament desmin was also not expressed yet. These results suggest that 
SPARC does not directly induce the expression of cardiomyogenesis specific factors.  
 
To see when Nkx2.5 expression is rising in differentiating CVPCs, an experiment with a 
larger time scale was designed. Besides the effects of M-LIF and BMP2 on Nkx2.5 
expression was investigated. CVPCs were treated with M-LIF, BMP2 and SPARC and 
combinations of M-LIF/BMP2 and M-LIF/SPARC and mRNA was isolated 24-, 48- and 72 
hours after treatment. In SPARC and M-LIF treated CVPCs Nkx2.5 was highly expressed 
after 48 hours. Whereas, in untreated and BMP2 or M-LIF/BMP2 treated cells Nkx2.5 
was up-regulated 24 hours later. The two experiments showed that SPARC does not 
directly up-regulate important pre-cardiac marker genes within 12 hours. In 
differentiating CVPCs both cardiomyogenesis promoting factors M-LIF and SPARC 
activated Nkx2.5 transcription between 24 hours and 48 hours after addition, whereas 
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in untreated and BMP2 treated CVPCs Nkx2.5 transcription was apparent within 48 -96 
hours.  
 
However, how Nkx2.5 gets activated by SPARC or M-LIF remained unclear. Literature 
suggests that the Wnt pathway promotes Nkx2.5 expression and cardiomyogenesis in 
general. SPARC physically interacts with ILK1 (Barker et al. 2005) and ILK1 is known to 
inhibit GSK3 (Dedhar 2000) thereby activating the canonical Wnt pathway. Wnt is an 
essential regulator of cardiac progenitor cell differentiation (Cohen et al. 2008) and 
promotes differentiation of mesodermal progenitors into CMCs in EBs (Kwon et al. 
2007). Furthermore, Wnt signaling promotes Nkx2.5 expression and early 
cardiomyogenesis in mouse embryonic carcinoma stem cells (Liu et al. 2009). 
Therefore, it is very likely that Wnt regulates differentiation in CVPCs as well. To test 
this hypothesis we wanted to inhibit GSK3 to activate the Wnt pathway and from the 
experiments done by Ying (Ying et al. 2008) the new specific GSK3 inhibitor CHIR99021 
was known. But in these experiments with mESCs CHIR99021 was used to keep mESCs 
pluripotent and not to induce differentiation. As CVPCs partly resemble mESCs and 
share the same transcription factors which maintain self renewal the effect of GSK3 
inhibition was unclear. In mESCs CHIR99021 and its inhibition of GSK3 was used to 
promote longevity and proliferation of mESCs. In our experiment we used the same 
concentration of CHIR99021 as in experiments with mESCs. In difference to prior 
experiments horse serum was used. This serum requires a higher concentration of 
CVPCs because CVPCs proliferate less. Horse serum is frequently used for myocyte 
differentiation and proved to be as effective as FBS for CVPC differentiation. Beating 
CMCs were observed from day 14 until day 26 in untreated CVPCs only. CVPCs treated 
with CHIR99021 remained undifferentiated with a small and round morphology. 
Almost no CMCs were observed in CHIR99021 treated CVPCs.  
 
Thus, indirect activation of the Wnt pathway by inhibiting GSK3 maintains CVPCs 
undifferentiated. The experiment showed that total inhibition of GSK3 inhibits 
differentiation indicating that activating the Wnt pathway inhibits cardiomyogenesis in 
CVPCs. Therefore, SPARC does not exclusively indirectly activate Wnt during CVPCs 
differentiation. However, the differentiation-inhibitory effect of CHIR99021 may be a 
result of the long term treatment which could be circumvented by using CHIR99021 at 
different time points or by using other concentrations of CHIR99021. Further 
experiments with temporal Wnt activation and Wnt inhibition should be done with 
differentiating CVPCs. 
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6 Conclusion 
All the results indicate that CVPCs, expressing stem cell markers, being able to self-
renew and showing a limited potency which is restricted to the cardiovascular system, 
can be regarded as progenitor cells of the heart. The existence of CVPCs confirms the 
evidence that the heart is not a post-mitotic organ and that cardiomyocytes, vascular 
smooth muscle cells and endothelial cells can be replaced by stem cells in vivo 
(Anversa et al. 2006).  
 
Although only cardiovascular cells were observed, all cells which develop during CVPCs 
differentiation should be identified by specific cellular markers. Furthermore, non-
cardiovascular cell types should be excluded. The different cell types which develop 
should be quantified by FACS (fluorescence activated cell sorting). The transcriptional 
profile of CVPCs should be completed and expanded with real time PCR during 
differentiation. A 3-dimensional matrix similar to heart tissue could enhance the 
differentiation of CVPCs. An in vivo model for medical applications could be 
constructed by engrafting CVPCs into infarcted hearts.  
SPARC is of special interest because it is expressed during heart formation in the 
embryo and in regeneration of muscle cells in vivo. In vitro SPARC enhanced the 
differentiation of CVPCs to CMCs. In vivo SPARC might induce regeneration of the 
heart as well. To be useful for medical applications all findings should be confirmed in 
human CVPCs. 
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8 Appendix 
8.1 Abstract 
The treatment of cardiovascular disease with regenerative stem cell therapy is a 
promising new field of medical science. To achieve a targeted differentiation of stem 
cells to heart cells, it is mandatory to understand which factors are responsible and 
which signalling pathways are regulated. The ability to isolate, cultivate and handle 
cardiovascular progenitor cells would ease directed heart-specific differentiation. 
By using a new method, cardiovascular progenitor cells (CVPCs) were isolated from 
heart tissue of neonatal mice and cultivated on feeder cells. CVPCs could be cultivated 
exactly like mouse embryonic stem cells (mESCs).  
Like in mESCs, the property of self renewal and to remain undifferentiated was 
observed in CVPCs during continuous propagation over 60 passages. Stem cell 
characteristics were demonstrated by detection of expression stem cell specific 
transcription factors Oct3/4, Sox2 and Nanog by reverse transcriptase polymerase 
chain reaction (RT-PCR). 
In vitro experiments in hanging drop culture, which were done exactly as in embryoid 
body experiments showed multipotency in CVPCs which is restricted to cardiovascular 
cells. Endodermal cells, smooth muscle cells and contracting cardiomyocytes were 
observed. Cardiac troponin T positive filaments were visualized by 
immunofluorescence. Differentiation experiments in common cell culture confirmed 
that CVPCs differentiate to cardiomyocytes autonomously. Mesodermal and heart 
specific markers were upregulated during differentiation.  
Differentiation was always dependent on cell density, indicating autocrine regulation. 
Secreted protein acidic and rich in cysteine (SPARC) is a glycoprotein which is secreted 
by parietal endoderm during embryogenesis. RT-PCR revealed that SPARC is also 
expressed in CVPCs in their undifferentiated and differentiated state. Under the 
chosen specific conditions, administering SPARC and administering the cytokine 
leukemia inhibitory factor (LIF) promoted the specific differentiation of CVPCs to 
cardiomyocytes. The cytokine bone morphogenetic factor 2 (BMP2) which belongs to 
the transforming growth factor β (TGF-β) super-family inhibited cardiomyogenesis in 
CVPCs. Specific inhibition of glycogen synthase kinase 3 α and β (GSK3 α/β), a negative 
regulator of the Wnt-pathway prevented differentiation of CVPCs. 
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8.2 Zusammenfassung 
Die Behandlung von kardiovaskulären Erkrankungen mittels regenerativer 
Stammzelltherapie ist eine vielversprechende, neue medizinische Heilungsmethode 
und Gegenstand zahlreicher Forschungsprojekte. Um eine gerichtete Differenzierung 
von Stammzellen zu Herzzellen zu ermöglichen, ist es dabei von großer Bedeutung 
herauszufinden, welche Faktoren dafür verantwortlich sind und welche Signalwege in 
der Zelle aktiv sind. Herz-Vorläuferzellen würden hierbei im Vergleich zu pluripotenten 
Stammzellen die gezielte Differenzierung zu Kardiomyocyten erheblich vereinfachen.  
Mit einer neuen Methode wurden kardiovaskuläre Vorläuferzellen (CVPCs) aus dem 
Herzgewebe neonataler Mäuse isoliert und auf Feeder Zellen kultiviert.  CVPCs 
konnten unter den gleichen Bedingungen wie embryonale Stammzellen der Maus 
(mESC) kultiviert werden. Wie bei mESC wurde eine hohe Fähigkeit zur 
Selbsterneuerung und zum Verbleib im undifferenzierten Zustand der CVPCs bei der 
kontinuierlichen Kultivierung über 60 Passagen festgestellt. Der Stammzellcharakter 
der CVPCs wurde auch durch den Nachweis der Expression der stammzellspezifischen 
Transkriptionsfaktoren Oct3/4, Sox2 und Nanog mittels Reverser-Trankriptase 
Polymerase Kettenreaktion (RT-PCR) demonstriert.  
In vitro Experimente in Kultur mit hängenden Tropfen, die ähnlich zu Embryoid Body 
Experimenten mit mESC durchgeführt wurden und bei denen sich sogenannte Cardiac 
Bodies bildeten, zeigten, dass CVPCs im Gegensatz zu mESC eine limitierte Potentialität 
besitzen, die auf kardiovaskuläre Zelltypen beschränkt ist. Es bildeten sich 
endodermale Zellen, glatte Muskelzellen und schlagende Kardiomyocyten. Das 
herzspezifische Protein Cardiac Troponin T konnte in den Cardiac Bodies mittels 
Immunfluoreszenz sichtbar gemacht werden. Auch in normaler Zellkultur zeigte sich, 
dass CVPCs autonom zu schlagenden Kardiomyocyten differenzieren. Mesodermale 
und herzspezifische Marker wurden während der Differenzierung hochreguliert.  
Die Differenzierung war dabei immer von der Zelldichte abhängig, was auf eine 
autokrine Regulierung der CVPCs hinwies. Secreted protein acidic and rich in cysteine 
(SPARC) ist ein Glykoprotein das während der Embryogenese vom parietalen 
Endoderm produziert wird.  Wie RT-PCR Experimente zeigten, wird SPARC aber auch in 
CVPCs sowohl im undifferenzierten Zustand als auch in der differenzierten Zelle 
transkribiert. Zugabe von rekombinantem SPARC zu CVPC Kulturen verstärkte die 
spezifische Differenzierung der CVPCs zu Kardiomyocyten. Unter den gewählten 
Bedingungen wurde eine erhöhte Differenzierung der CVPCs zu Kardiomyocyten durch 
das Zytokin Leukemia Inhibitory Factor (LIF) ausgelöst. Bone morphogenetic factor 2 
(BMP2), ein Zytokin der transforming growth factor beta (TGFβ) Superfamilie, 
inhibierte die Kardiomyogenese in CVPCs. Spezifische Inhibierung der Glykogen 
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Synthase Kinase 3 α und β (GSK3) ein negativer Regulator des WNT Signalweges 
verhinderte eine Differenzierung der CVPCs. 
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